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HLA-G molecules in infections and autoimmune diseases  
 
Abstract 
Human leukocyte antigen-G (HLA-G) is a non-classical HLA class I molecule that differs 
from classical HLA class I molecules for low allelic polymorphism and restricted tissue 
distribution. HLA-G is a tolerogenic molecule with an immune-modulatory and anti-
inflammatory function on both innate and adaptative immunity. This peculiar characteristic of 
HLA-G molecule has led to evaluate its role in pathological conditions in order to define a 
possible use in diagnosis, prevention and treatment of diseases. Recently, HLA-G molecule 
has been shown to have an important implication in different inflammatory and autoimmune 
diseases, pregnancy complications, tumor development and severity, and susceptibility to 
viral infections. HLA-G molecules have been reported to be present differences at both 
genetic and protein levels in different disease situations, supporting its crucial role as a 
suitable key actor in pathological conditions. In fact, specific diseases show altered levels of 
soluble (s)HLA-G and different HLA-G gene polymorphisms correlated with disease 
outcome. Thus, HLA-G may exhibit two distinct effects in pathological conditions: it could 
be protective in inflammatory and autoimmune diseases or it could be dangerous, for 
example, in tumors or infectious diseases. 
In this thesis, I report my results on HLA-G molecule analysis in different pathological 
conditions: microbiological infections and autoimmune diseases.  
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Introduction  
 
1. Human Major Histocompatibility Complex 
 
The human Major Histocompatibility Complex (MHC) is composed by a series of molecules 
encoded by a set of genes (~130) located on the short arm of chromosome 6 (6p) that are 
responsible for lymphocyte recognition, "antigen presentation" and immune response 
regulation. This gene complex comprises several distinct loci that in humans are called HLA, 
which stands for Human Leucocyte Antigens. MHC antigens can be subdivided into three 
major classes: class I, class II and class III (Figure 1). The class I and class II antigens are 
expressed on cells and tissues while class III antigens are present mainly as serum and body 
fluid proteins (e.g.C4, C2, factor B, TNF, complement components). In the class I gene 
complex are present three major loci: A, B and C. Each of these loci encodes for an alpha-
chain polypeptide that associates to ß2-microglobulin, encoded by a gene on chromosome 15. 
The class II gene complex contains at least three loci, DP, DQ and DR, which encode for one 
alpha- and one beta-chain polypeptide associated together to form the class II antigens. All 
together, MHC class I A, B and C are considered as “classical” MHC class I antigens (MHC 
Ia). In fact, in addiction to those molecules, another group of MHC molecules, called non 
classical MHC class I molecules or MHC Ib (HLA Ib in humans) started to be studied in the 
end of the 80’s [1,2].  
 
 
 
Figure 1. Schematic representation of the HLA region on chromosome 6. The non 
classical HLA class I gene are represented in grey. 
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2. The non classical HLA class Ib genes 
 
Non-classical MHC class Ib molecules are closely homologous to classical class Ia molecules 
but are distinguished by their limited polymorphism and low cell surface expression. The 
group class Ib is composed by three molecules: HLA-E, HLA-F and HLA-G. The class Ib 
molecules do not represent just vestigial evolutionary remnants of classical class Ia 
molecules; rather some exhert highly specialized functions, as testified by their conservation 
between different species. In particular, human HLA-E (Qa-1 in mouse) and HLA-G (Qa-2 in 
mouse) constitutes a clear homology between species. In 1993, Warner et al. [3] demonstrated 
a reproductive advantage in mice encoding Qa-2 molecules, evidencing in this way the 
importance of the molecule in pregnancy outcome [4]. On the basis of these characteristics, 
Qa-2 and HLA-G antigens seem to share not only structural but also functional similarities in 
the regulation of immune response, through interaction with both inhibitory and activatory 
receptors [5,6].   
 
3.The HLA-G antigen 
 
HLA-G antigen is a non-classical HLA class I molecule characterized by (i) a low allelic 
polymorphism, (ii) a restricted tissue distribution, (iii) mRNA alternative splicing that 
generates seven proteic isoforms and (iv) a tolerogenic and anti-inflammatory biological 
function [7]. 
The basic characteristics of HLA-G biology have been further described at different levels [8 
paper attached] 
 
3.1. The HLA-G gene 
 
The HLA-G gene shows low allelic polymorphisms with 50 HLA-G alleles acknowledged in 
the coding region (IMGT HLA database, October 2014). HLA-G gene has also polymorphic 
sites at the 5’-upstream regulatory region (5’ URR) and at the 3’-untranslated region (3’ UTR) 
which may contribute to the regulation of HLA-G expression [9]. For example, one of the 
most studied HLA-G polymorphism is a 14 bp insertion/deletion polymorphism (rs16375) 
[10] in exon 8 in the 3’ UTR which is associated with mRNA stability and HLA-G protein 
expression [11, 12] (Figure 2). The presence of an insertion of 14 bp in the gene identify the 
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allele ins that has been associated with lower levels of HLA-G expression than the allele with 
the 14 bp deleted (del) [12-14]. An additional alternatively spliced HLA-G transcripts lacking 
92 bp of the first part of exon 8 is observed within the insertion of 14 bp allele and is 
characterized by a more stable transcript [15]. Another polymorphism widely studied regards 
one single nucleotide polymorphism (SNP) C>G at the +3142bp position (rs1063320) that has 
been explored by Tan and coauthors [16]. The presence of a guanine at the +3142 position 
may influence the expression of the HLA-G locus by increasing the affinity of this region for 
the microRNAs miR-148a, miR-148b and miR-152, therefore decreasing the mRNA 
availability for translation by mRNA degradation and translation suppression. The influence 
of the +3142G allele has been demonstrated by a functional study in which HLA-G high-
expressing JEG-3 choriocarcinoma-derived cells have been transfected with miR-148a, 
decreasing soluble HLA-G levels. The contrasting results obtained by Manaster and coauthors 
[17], who have reported the absence of +3142C>G effect on the miRNA control of membrane 
HLA-G expression, prompt further considerations on the relationship between this 
polymorphism and membrane HLA-G expression. 
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Figure 2. Multiple HLA-G proteins derived from alternative splicing of HLA-G mRNA. 
A: The HLA-G gene is composed of 8 exons. The α, intracellular and transmembrane 
domains and the 14 bp insertion/deletion polymorphism (rs16375) in exon 8 in the 3’ 
untranslated region (UTR) are represented.  
B: The gene is alternatively spliced to yield 7 transcripts. In two of these, a stop sequence in 
intron 4 results in soluble isoforms. 
C: The 7 HLA-G proteic isoforms: four membrane-bound (HLA-G1, -G2, -G3, -G4) and three 
soluble (HLA-G5, -G6, -G7) molecules; multimeric conformations of HLA-G molecules 
 
 
 
Classical MHC class I genes are transactivated by two groups of juxtaposed cis -acting 
regulatory modules: (i) the up-stream enhancer A and ISRE (interferon-sensitive response 
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element) which mediate the constitutive and cytokine-induced expression; (ii) the S-X-Y 
module which controls the constitutive and CIITA (class II transactivator) mediated 
transactivation. These modules are divergent in HLA-G gene that is unresponsive to NF-
kappaB (nuclear factor-kappaB), IRF-1 (interferon regulatory factor 1), and CIITA mediated 
induction pathways [18, 19]. The HLA-G gene promoter contains a putative interferon-
regulatory factor (IRF)-1 binding site 746 base pairs upstream from ATG, which is distinct 
from the interferon-responsive element within proximal class Ia gene promoters. This control 
region is the probable element, which mediates interferon beta-induced expression of the 
HLA-G gene [20]. 
It was also reported that IFN-ߚ enhances HLA-G expression throught the interaction with a 
ISRE present next to the nonfunctional interferon-gamma activated site (GAS) element at 
positions −754 to −743 [21]. HLA-G enhancer A and ISRE seem to bind only the 
constitutively expressed factor Sp1 (also known as Specificity Protein 1) [22, 23] but this 
binding of Sp1 does not modulate the constitutive or IFN-induced transactivation of  HLA-G 
[24]. Furthermore, in the HLA-G promoter are present three cAMP/PMA response elements 
(CRE/TRE) with binding affinity for REB (rice endosperm bZIP)/ATF (activating 
transcription factor-2) and Fos/Jun proteins. It has been reported that HLA-G transactivation is 
regulated by CREB (cAMP-response element-binding protein), CREB-binding protein (CBP), 
and p300. These features represent the unique regulation of HLA-G transcription among the 
MHC class I genes [25] (Figure 3) 
HLA-G expression is also regulated by epigenetic mechanisms [26, 27], such as  DNA 
methylation. In fact, the role of methylation on HLA-G expression has been tested in human 
tumours considering the effect of the methylation inhibitor 5-aza-deoxycytidine on the CpG-
enriched regulatory region of the HLA-G gene. The 5-aza-dC treatment results in 
hypomethylation of putative control sequences within the 5' regulatory region of HLA-G and 
these changes in methylation correlate with a significant increase in expression [28, 29]. 
The HLA-G gene seems not to undergo genomic imprinting, in fact it is co-dominantly 
expressed on trophoblast cells [30].  
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Figure 3. Regulation of HLA-I promoters  
 
HLA-G molecules are also regulated by post-transcriptional mechanisms [31], including 
alternative splicing, mRNA stability, translation and protein transport to the cell surface [30-
32]. This is possible due to the expression in advance of the molecules that are essential for 
cell surface expression
 
of class I molecules, ß2-microglobulin (ß2m) and the transporter
 
for 
antigen processing proteins (TAP1 and TAP2). 
 
 
3.2. HLA-G expression and function 
 
In physiological conditions HLA-G protein presence is restricted to certain tissues such as 
trophoblast, thymus, cornea, pancreas, proximal nail matrix, erythroblast, endothelial 
precursors and mesenchymal stem cells [33-35]. 
Unlike HLA class Ia antigens, seven HLA-G isoforms are generated by alternative splicing of 
its primary transcript and differential association with ȕ2-microglobulin (ȕ2-m) [36]: four, 
HLAG1,-G2, -G3 and -G4, are membrane-bound, while three, HLA-G5, -G6 and -G7, are 
soluble molecules (Figure 2). The soluble isoforms retain the intron 4, which includes a stop 
codon and leads to the termination of the mRNA translation before the transmembrane 
domain. The HLA-G1 and HLA-G5, the most analysed isoforms, are the only structures that 
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contain three alpha domains, while the other isoforms lack one or more globular domain. 
Furthermore, the proteolytical cleavage of surface isoform HLA-G1 generates the soluble 
HLA-G1 form (sHLAG1) [37]. Several evidences indicate that the soluble HLA-G1 (sHLA-
G1) form is generated through the shedding of the membrane bound HLA-G1 by 
metalloproteinase (MMP) [38, 39]. In particular, our group identify that Matrix 
Metalloproteinase-2 (MMP-2), a zinc-containing and calcium-requiring endopeptidase known 
for the ability to cleave several extracellular matrix constituents, as well as non-matrix 
proteins, is responsible for HLA-G1 membrane-shedding via three possible highly specific 
cleavage sites [40 paper attached]. 
An in frame termination codon in HLA-G exon 6 leads to a truncated cytoplasmic tail which is 
19 amino acids shorter than the corresponding tails of HLA-A, -B and –C proteins. This 
feature prevents the signal transduction from the cell surface to the nucleus. However, the 
membrane-bound HLA-G can localize in lipid rafts and can act as a signaling molecule, via 
modification of the phosphorylation state of raft-localized proteins [41]. This differs from 
classical HLA-I, which are recruited in lipid rafts upon receptor engagement [42]. 
The HLA-G production could be enhanced by different stimuli, such as interleukin 
(interleukin-10), interferon gamma and hormone molecules [43].  
The anti-inflammatory and immunosuppressive Interleukin (IL)-10 has been correlated with 
concomitant HLA-G expression [13]. Transactivation of HLA-G transcription has also been 
demonstrated by leukemia inhibitory factor (LIF) [44] and methotrexate cell exposure [45]. 
Furthermore, interferon (IFN)-α, -ß and –Ȗ enhance HLA-G cell-surface expression by tumors 
or monocytes [46, 47]. HLA-G expression could be acquired by trogocytosis [48], where a 
“donor” cell that expresses membrane HLA-G exchanges membrane parts containing HLA-G 
with a “recipient” cell that is not expressing HLA-G molecules. In this particular situation, 
“recipient” cells will acquire and make use of membrane HLA-G molecules from a “donor” 
HLA-G positive cell without the activation of HLA-G gene transduction into protein. HLA-G 
molecules undergo the trogocytosis mechanism: some effectors CD4 and CD8 T lymphocytes 
acquire immunosuppressive HLA-G1 molecules from antigen presenting cell membranes and 
reverse their function from effectors to regulatory cells [49]. 
 Trogocytosis of HLA-G from antigen presenting cell (APC) by T cells in humans makes 
these T cells unresponsive [48]. It has been shown that NK cells can acquire HLA-G1 from 
tumor cells, which provokes an arrest of NK cells proliferation and cytotoxic activity, 
behaving like suppressor cells capable of inhibiting other NK-cell functions [50]. 
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Membrane-bound HLA-G1 and  soluble HLA-G (HLA-G5 and sHLA-G1) molecules exert 
immunosuppressive effects: (i) inhibit the cytotoxic activity of CD8 positive T lymphocytes 
(CTL) and Natural Killer (NK) cells [51], (ii) induce the apoptosis of NK and activated 
cytotoxic T cells [52], (iii) inhibit the allogeneic CD4 positive T-cell proliferation and 
interfere with naïve CD4 T-cell priming [53], (iv) inhibit antigen presenting cell  and B 
lymphocyte differentiation [54], (v) induce regulatory T cells [55] (Figure 4). Furthermore, 
sHLA-G affects angiogenesis interacting with endothelial cells [56] and induces resting NK 
cells to produce chemokines and cytokines [12]. 
HLA-G exerts its immunomodulatory functions through the interaction with multiple 
receptors  expressed by immune cells (Figure 4). HLA-G is known to interact with NK 
receptor [57, 58], as KIR2DL4 [5, 12] and leukocyte inhibitory receptors (LILRs) / 
immunoglobulin-like transcripts (ILT) [6, 13] as LILRB1 (LIR-1/ILT2/CD85j), which is 
highly expressed on T and B-lymphocytes and with LILRB2 (LIR-2/ILT4/CD85d), present 
mainly in monocytes/macrophages. The alpha3 domain of HLA-G is the putative binding site 
for ILT receptors [59] while the residues Met76 and Gln79 in the alpha1 domain play a 
critical role in the recognition of KIR2DL4 receptor [60]. The KIR2DL4, receptor of the killer 
cell immunoglobulin-like receptors (KIR) family, is expressed in all NK cell types and has 
unique structural properties among the rest of KIR receptors: it possesses a long cytoplasmic 
tail characteristic of inhibitory receptors, a charged amino acid in the transmembrane domain 
similarly to activating KIR receptors [61], and a mix structure in the extracellular part with 
D0 and D2 domains. Contrary to other KIR receptors, KIR2DL4 expression is transitory on 
NK cell surface, with a main expression in endosomes, reached by an endocytic process. 
KIR2DL4 seems to participate to HLA-G endocytosis when it is transitory expressed on NK 
cell surface, as both HLA-G and KIR2DL4 can be simultaneously co-localized in endosomes 
[5]. KIR2DL4 expression can be induced by IL-2 and its activation upon antibodies 
engagement provokes a weak cytotoxic activity with a strong IFN-Ȗ production [62]. In-vitro 
studies have shown that KIR2DL4 is able to interact with ȕ2-m free HLA-G molecules, 
inducing IFN-Ȗ production [63] and increasing NK cell cytotoxicity [64]. Contrary to LILR 
receptors, KIR does not bind HLA-I molecules through its α3 domain, but through α1 and α2 
domains which are much more polymorphic than α3 domain [65, 66]. This could account for 
the broader specificity of LILR receptors in comparison with KIR2DL4, that binds 
specifically HLA-G and not other HLA-I molecules.  
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The expression of LILRB1, LILRB2 and KIR2DL4 can be induced by HLA-G without any 
co-stimulatory requirement, which indicates that it can occur independently from any immune 
response [67]. 
Soluble HLA-G has potentially a higher range of activity than membrane-bound HLA-G. The 
circulating isoforms could bind to the same sets of leukocytes and perform exactly the same 
functions also systemically. 
The membrane-bound and soluble HLA-G proteins
 
have monomer, dimer, and oligomer 
forms (Figure 2); the dimer seems to have a dominant effect on the LILRB signaling. 
In fact, in vitro studies have reported that HLA-G1 is able to form disulphide-linked 
homodimers on cell surface [68-70] that bind ILT2 receptors with more avidity compared to 
monomers [71]. On the contrary, structural studies suggest that KIR2DL4 cannot bind HLA-
G dimers due to steric reasons [72]. 
 A disulfide-bonded dimer conformation is possible for the presence of a cysteine 42 residue 
that is present only in the heavy chain α1 domain of HLA-G [59, 68]. Besides Cys residues in 
α 2 and α 3 domains that allow intramolecular disulphide bonds, HLA-G molecule presents 
other important Cys residues. Cys42 in α1 domain and Cys147 in α 2 domain can form 
intermolecular disulphide bonds giving rise to HLA-G dimers that can be observed by 
SDS/PAGE under non-reducing conditions [69]. These structures have been observed for all 
HLA-G isoforms except HLA-G3 [73]. 
 Dimers of HLA-G have been observed on the surface of transfected cells [68], on 
choriocarcinoma cell line JEG-3 [74], on first trimester trophoblast cells [75] and on 
malignant cells [76]. Furthermore, a recent work of Ezeakile M et al. reported the importance 
of HLA-G dimers in kidney allograft outcome [77]. In fact, the authors decribed the presence 
of HLA-G dimers in plasma of kindney transplant patients together with an increased 
expression of membrane-bound HLA-G in association with prolongation of allograft survive.  
Alegre E. et al also reported that other HLA-G complexes exist in vivo as ubiquinated protein 
in exosomes [78] 
 
Soluble HLA-G1 is able to inhibit endothelial cells through specific interaction with the 
CD160 molecule, a glycosylphosphatidylinositol-anchored, major histocompatibility complex 
(MHC) Class I-dependent, immunoglobulin-like receptor, that is expressed by activated 
endothelial cells [56] (Figure 4). This interaction seems to lead to apoptosis of endothelial 
cells required for normal placental development. 
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Figure 4. HLA-G receptors. HLA-G receptors expressed on immune (CD8 T and CD4 T 
cells, B cells, natural killer (NK) cell, macropages, dendritic cells) and endothelial cells. ILT: 
immunoglobulin-like transcript; KIR: killer inhibitory receptor; TCR: T cell receptor. 
  
 
Figure 4. 
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Results  
 
1. Role of HLA-G molecules in pathological conditions 
 
The HLA-G expression has been analyzed in different pathological conditions, such as 
transplantation, oncology, viral infections, inflammatory and autoimmune diseases indicating 
that HLA-G can favour graft tolerance, tumor cell and virally infected immune escape and 
control the inflammatory conditions [79-82 paper attached, 83].  
I will report my results, obtained during my PhD course, on HLA-G analysis in different 
pathological conditions: microbiological infections and autoimmune diseases.  
 
1.1 HLA-G and infections 
Host immune defence is normally able to eliminate the majority of viral and bacterial 
infections. However, it is known that some pathogens, in particular viruses, have developed 
different mechanisms for subverting host immune defences, thus facilitating their spread in 
the host [84]. For instance, viruses can protected themselves against attack by NK cells by 
expressing HLA-G on the infected cell surface providing in this way an immunosuppressive 
effect. Anyway, the diminished immune function induced by HLA-G in the host could 
represent an advantage for virus progression by helping viruses subvert the host’s antiviral 
defences [85]. HLA-G can affect all the phases in the immune response: differentiation, 
proliferation, cytolysis, cytokine secretion, and immunoglobulin production. In fact, during 
infections, HLA-G modulates adaptive and innate immunity by interacting with T or B-
lymphocytes and NK cells or polymorphonuclear cells (Figure 1). 
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Figure 1: Causes and consequences of HLA-G modulation in infectious diseases. Positive 
and negative effects of HLA-G are shown in blue and red, respectively. Parasites, bacteria, or 
viruses induce the secretion of various cytokines, including IL-10 and interferon (-ߛ for 
bacterium and IFN-ߙ and -ߚ for virus). These cytokines upregulate the expression or secretion 
of HLA-G. In addition, IL-10 induces IL-10-producing human dendritic cells (DCs), termed 
DC-10, expressing HLA-G and ILT4. HLA-G induces tolerogenic DC in addition to DC-10 
and regulatory cells via direct interaction with ILT2 and/or ILT4. HLA-G, through direct 
interaction with ILT2, inhibits the function of T and NK cells and B cells, whereas it inhibits 
the function of granulocytes and myeloid DC via direct interaction with ILT4. Indirect effects 
of HLA-G are mediated by the induction of HLA-E cell surface expression, which inhibits 
CD94/NKG2a on NK and T cells.The consequence of HLA-G action is a downregulation of 
innate and adaptive immunity. (Immunomodulatory Properties of HLA-G in Infectious 
Diseases, Amiot L et al. J. Immunol Res 2014 [86]). 
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Even if host immune system presents several mechanisms to control infections, the viruses, in 
particular, have developed several strategies to counteract host immune defenses [84], for 
example by using  HLA-G functions in viral immune-escape from immune cells [85]. HLA-G 
modulation exherted by pathogens has the aim to affect its expression in different ways, for 
example exploiting gene polymorphysms and alleles, modifying the exposition or the 
secrection of the protein or producing homologue proteins to human cytokines [86]. 
1.1.1 HLA-G and viral infections 
During viral immune-escape, HLA-G could be modulated at different levels affecting the 
expression of HLA-G on the infected cells [86]. Firstly, HLA-G polymorphism is involved in 
susceptibility to viral infections. In fact, its implication in viral immune-escape is deeply 
described for example during HIV 1 infection [87-92]. These studies reported that some 
HLA-G alleles (in particular the G*010108 allele) and polymorphisms (i.e. 14bp ins/del and 
+3142 C>G)  that can influence HLA-G expression have been associated with a greater risk 
of HIV infection and also of horizontal transmission. Concerning the role of HLA-G, and in 
particular its polymorphisms during viral infections, we identify two polymorphisms in the 3’ 
untranslated region of the HLA-G gene (3’ UTR) (14 bp ins/del, +3142C>G) that are  
involved in susceptibility to Human papillomavirus (HPV) infection [93 paper attached] 
reporting characteristic patterns among the different kind of lesion developed. It is well 
known that HPV is necessary but not sufficient to induce cancer development [94] and that it 
interferes with host immune response by modifying the expression of human leukocyte 
antigen-G (HLA-G) [95]. Moreover, previous studies already confirmed that HLA-G 
polymorphisms could influence HPV infections susceptibility and lesion development [96-
99]. Indeed, we reported that the 14 bp del allele is associated with a high risk of HPV 
infection, and the del/C haplotype facilitates the development of invasive cervical cancer [93 
paper attached], suggesting in this way that HLA-G polymorphisms could represent a risk 
factor for neoplastic transformation expecially in high-risk HPV positive subjects, that are 
known to be more likely to cancer progression [100]. It is known by literature that HLA-G is 
also implicated in chronic hepatits B pathogenesis [101, 102] and we reported the importance 
of 14 bp ins/del polymorphism influence also concerning Hepatitis B virus (HBV) infection. 
Our study revealed an association between the 14 bp ins/del polymorphism and an enhanced 
HBV activity in presence of high HBV DNA levels [103 paper attached]. 
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In general, viral proteins are able to decrease HLA class I expression, but their effect on 
HLA-G expression at the cell surface is more ambiguous. Indeed, they may have no effect 
[104-106] or an inhibitory effect [107-110], or as reported by Onno et al. [111], even induce 
HLA-G after viral reactivation in activated macrophages infected by hCMV. By contrast, 
another study reported that HLA-G1 expressed on cell surface resulted downregulated and 
that this decrese was due to hCMV short viral US glycoproteins [109]. In fact, hCMV 
produces different US proteins that act on MHC expression at different levels (Figure 2) and 
show differential effects on the expression of classical HLA class I and HLA-G molecules at 
the cell surface. This different effect is due to the shorter cytoplasmic tail of HLA-G [112] 
and other structural characteristics.  
 
Figure 2. Model for immune escape in hCMV infection. 
These conflicting results for hCMV may depend on different cell types studied (monocytes, 
trophoblasts, or the U373-MG astrocytoma cell line). In fact, the viral proteins exhibit 
different effects depending on the infected cell target, the type (classical or otherwise) of HLA 
class I molecules, and the membrane-bound or soluble nature of the HLA-G protein. For 
example, US10 recognizes the short cytoplasmic tail of HLA-G (RKKSSD) as a substrate and 
downregulates the cell surface expression of HLA-G but not that of classical class I MHC 
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molecules [109]. On the other hand, the US2 protein affects levels of HLA class I molecules 
by increasing proteasome-mediated degradation, unlike HLA-G1, which lacks the residues 
essential for interaction with US2 [104]. Furthermore, HLA-G1 could also be targeted for 
degradation, independently of the cytoplasmic tail 105]. In the case of HIV infections, the 
short cytoplasmic tail of HLAG avoids Nef-induced downregulation, whereas Nef 
downregulates MHC class I molecules [105, 113].  
Basing on this peculiarity of hCMV in modulating HLA-G expression, we evaluate the 
possible role of HLA-G in pregnant women ondergoing primary hCMV infection. In fact, 
about 1-7% of pregnant women present a primary hCMV infection, with a transmission rate 
to the fetus of 30–40%. Plasma samples from  pregnant women  (divided according to their 
infectous status in: uninfected,  with primary hCMV infection and with non primary hCMV 
infection), from non-pregnant women and amniotic fluids corresponding to primary infected 
women were analyzed for hCMV presence and soluble HLA-G (sHLA-G) levels. We 
observed an increased expression of sHLA-G molecules in plasma samples from primary 
infected women. Moreover, amniotic fluids from fetuses symptomatic for hCMV infection 
presented higher sHLA-G levels, were mainly characterized by sHLA-G1 isoform, presence 
of HLA-G heavy chain and a concentration gradient to the maternal plasma. Our result 
supported the hypothesis that the determination of sHLA-G molecules in both maternal 
plasma and amniotic fluid represents a predictive marker for perinatal outcome in fetuses with 
HCMV infection [114 paper attached].  
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Abstract  
Background: Human leukocyte antigen (HLA)-G molecules are non classical HLA class I 
antigens expressed as membrane bound and soluble isoforms (sHLA-G) with a restricted 
tissue distribution and immune-regulatory functions. They are expressed at the fetal-maternal 
interface and have an important role in the maintenance of a tolerogenic condition. Previous 
researches reported an influence of HCMV infection in HLA-G molecule expression. The 
objective of this research was to identify maternal and fetal characteristics as prognostic 
markers of congenital human cytomegalovirus (HCMV) infection.  
Methods: Plasma samples from 130 pregnant women  (30 uninfected, 56 with primary 
HCMV infection, 44 with non primary HCMV infection), 52 non-pregnant women and 56 
amniotic fluids corresponding to primary infected women were analyzed for HCMV presence, 
soluble HLA-G (sHLA-G), classical sHLA-I, beta-2microglobulin levels.  
Results: We observed an increased expression of sHLA-G molecules in plasma samples from 
primary infected women. Amniotic fluids from fetuses symptomatic for HCMV infection 
presented higher sHLA-G levels, were mainly characterized by sHLA-G1 isoform, presence 
of HLA-G heavy chain and a concentration gradient to the maternal plasma.  
Conclusions: Our results suggest the determination of sHLA-G molecules in both maternal 
plasma and amniotic fluid as a  predictive marker for perinatal outcome in fetuses with 
HCMV infection. 
 
Key words: HLA-G; cytomegalovirus; pregnancy 
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Introduction  
Human cytomegalovirus (HCMV) is the most common cause of intrauterine infection, 
occurring in 0.3% to 2.3% of  births [1]. HCMV intrauterine transmission is more common 
after  primary infection (30-40% of probability) than  after secondary/recurrent  infection 
(1%) [2, 3]. Ten to fifteen percent of congenitally infected infants will have symptoms at birth 
and around 10% of them will die. 70-80% of surviving babies will suffer delayed sequelae 
such as sensorineural hearing loss, delay of psychomotor development, and visual impairment 
[4]. Most congenital infected infants (85–90%) have no symptoms at birth, but 8% to 15% of 
them will develop delayed injury [3, 4].  
Within 20-21 weeks of gestation prenatal diagnosis is offered to women with proven primary 
HCMV infection occurring before 14-16 weeks of gestation. The fetal compartment can be 
studied by invasive (amniocentesis) and non-invasive (ultrasound examination) techniques 
[5]. Ultrasonographic findings are helpful but not diagnostic because HCMV has features in 
common with other intrauterine infections and its sensitivity is poor [6]. HCMV detection in 
amniotic fluid with virus isolation and/or Real Time PCR  is  useful for prenatal diagnosis of 
fetal infection, due to its high sensitivity and specificity [7]. Low viral loads in amniotic fluids 
with negative ultrasound findings are  associated with asymptomatic congenital HCMV 
infection. However, high viral loads with negative ultrasound findings may be associated with 
symptomatic or asymptomatic congenital HCMV infections [8-10]. 
Therefore, there is still a need for reliable  prognostic factors for the outcome of HCMV  fetal 
infection.  
HCMV can modulate the expression and/or function of human leukocyte antigens (HLA), by 
encoding proteins to detain and destroy the expression of HLA molecules on the surface of 
infected cells or selectively up-regulate specific HLA class I molecules binding to immune 
cell inhibitory receptors [11]. In this scenario, there is an interesting non-classical HLA class I 
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antigen, HLA-G, characterized by  low allelic polymorphism, restricted tissue distribution and 
alternative mRNA splicing which creates different isoforms, 4 membrane-bound (HLA-G1–
G4) and three soluble (HLA-G5–G7) [12]. HLA-G is expressed at the maternal-fetal 
interface, on surface of trophoblasts [13] and soluble HLA-G in plasma (sHLA-G) increases 
during the first trimester of pregnancy [14]. HLA-G is responsible for reprogramming the  
local maternal immune response towards tolerance and remodelling  uterine vascularization 
[15]. The importance of HLA-G production during pregnancy is evident in pre-eclampsia and 
in unexplained recurrent spontaneous abortions, where HLA-G expression in placenta is 
reduced [16]. HLA-G has tolerogenic functions, inducing apoptosis of activated CD8+ T cells 
[17], acting on T regulatory cells [18], modulating the activity of natural killer cells [19] and 
dendritic cells [20] and blocking allo-cytotoxic T lymphocyte response [21]. HCMV infection 
modifies HLA-G expression in tissues and immune cells, with a downmodulation  in infected 
cytotrophoblasts  [22] and upregulation  in  infected peripheral blood cells [23]. Specific 
HCMV proteins increase HLA-G expression interacting with the HLA-G promoter, and 
affecting mRNA stability, protein translation and the secretory pathway [22, 24-27]. The 
increase in HLA-G expression  is suggested as a mechanism for virus immune escape, 
because of the immune-inhibitory functions of HLA-G.   
Since HLA-G has an important role during pregnancy and HCMV  modifies its expression, 
we analyse the role of HLA-G in congenital infections. Moreover, it has been observed that 
one important component of HLA-I molecules, beta-2 microglobulin (b2M), has diagnostic 
efficacy for differentiating symptomatic from asymptomatic HCMV  congenital infection 
[28]. Since free-b2M mainly derives from the shedding of HLA-I-b2M associated molecules 
and HLA-G molecules generate free-heavy chains releasing b2M during specific conditions 
[29, 30], we supposed a role for HLA-G antigens in generating b2M-free molecules.  
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To explore the possible role of HLA-G molecules in congenital HCMV infection, we 
analyzed maternal and fetal classical HLA-I, HLA-G and beta-2microglobulin expression in 
correlation with the risk of HCMV congenital infection.  
 
Materials and Methods 
Subjects 
The study analyzed a cohort of 130 pregnant women who were referred between 2006 and 
2011 to the Maternal-Fetal Medicine Unit, St. Orsola-Malpighi University Hospital, Bologna, 
for suspected primary  HCMV infection.  Maternal primary HCMV infection was assessed at 
the Virology Unit of the same University Hospital. Fifty-six amniotic fluid samples from 
primary HCMV infected women were collected during amniocentesis. Written informed 
consent was obtained from each woman before amniocentesis.  
The women, aged between 18 and 40 years, were in the first and second trimester of 
pregnancy. They presented no previous autoimmune and inflammatory diseases and they were 
no assuming anti-inflammatory or immune-modulatory drugs. 
Primary infection was diagnosed on clinical history as well as HCMV IgM-positive and 
low/moderate HCMV IgG avidity results, positive DNAemia and/or seroconversion for 
HCMV. Non primary maternal HCMV infection was diagnosed, within the first 16 weeks 
gestation, according to blot-confirmed IgM-positivity with high avidity anti HCMV IgG and 
presence of DNA-HCMV in blood and/or urine and or/saliva. HCMV-seronegative women 
(for both IgG and IgM) were defined as uninfected. 
Detection of HCMV fetal infection was performed on amniotic fluid samples with virus 
isolation and real-time PCR. The results of viral tests were confirmed by histological 
examination on terminated fetuses or testing urine of neonates within the first 2 weeks of life. 
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Fifty-two non-pregnant women were recruited as healthy controls.  
 
Diagnosis of symptomatic HCMV infection in fetuses and infants 
Fetal symptomatic infection was defined as the presence of ultrasound abnormalities and 
histological and immunoistochemical findings in fetal organs with particular attention to the 
brain of  aborted or dead in utero fetuses [31]. Congenitally infected newborns were assessed 
by clinical, instrumental and laboratory findings for disease in the neonatal period and 
subsequent monitoring up to 6 years [32]. 
 
Anti-HCMV IgM and IgG detection and IgG-avidity 
Maternal serum samples were tested using the Enzygnost® HCMV IgM  and IgG assays 
(Siemens Healthcare Diagnostics) and an in-house immunoblot for detection of HCMV-
specific IgM [33]. HCMV IgG avidity was tested with the Radim® Cytomegalovirus IgG 
Avidity EIA WELL assay (Radim). 
 
Virological examinations 
HCMV isolation from amniotic fluid was performed by shell-vial procedure as described 
elsewhere [34]. DNA was extracted from amniotic fluid and saliva with the NucliSens 
easyMAG System (bioMerieux) and from blood and urine with the QIAsymphony SP/AS 
System (QIAGEN). 
HCMV-DNA was quantified with a real-time PCR assay (HCMV ELITe MGB kit, 
ELITechGroup) using the ELITe-MGB technology. Amplification, detection, and analysis 
were performed with the ABI PRISM 7300 platform (PE Applied Biosystems). The detection 
limit was 11 copies/reaction and viral load was reported as number of copies/mL for all body 
fluids examined. 
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Enzyme-Linked Immunosorbent Assay (ELISA) for soluble HLA-G 
sHLA-G levels in plasma and amniotic fluid samples were assayed in triplicate as previously 
reported [35] using the monoclonal antibody (MoAb) MEM-G9 (Exbio), which recognizes 
the HLA-G molecules, in ȕ2-microglobulin associated form. The intra-assay coefficient of 
variation (CV) was 1.4% and the inter-assay CV was 4.0%. The limit of sensitivity was 1.0 
ng/ml. 
Plasma and amniotic fluid concentrations of HLA-G5/G6 were quantified as previously 
reported [36], using the 5A6G7 MoAb (Exbio). The intra-assay coefficient of variation (CV) 
was 2.0%, the inter-assay CV was 3.5%. The limit of sensitivity was 1.0 ng/ml. The amount 
of sHLA-G1 was expressed by the difference between sHLA-G and HLA-G5/-G6 
concentrations [36].  
 
ELISA for soluble HLA-I 
Plasma and amniotic fluid concentrations of sHLA- I were measured as previously reported 
[37] using an anti-HLA class I monoclonal  antibody (W6/32, ATCC). The amount of sHLA-
Ia was expressed as the difference between sHLA-I and sHLA-G concentrations since 
monoclonal antibody W6/32 used in our ELISA procedure detects both  classical sHLA-I (A, 
B, C) and  non-classical sHLA-G. 
 
ELISA for soluble Beta-2microglobulin and Albumin 
Beta-2microglobulin (b2M) concentration was determined in triplicate using a commercial  
Human beta-2microglobulin ELISA Kit (Abcam) with a detection limit <6 pg/ml. 
Albumin concentration was determined in triplicate with a 1:200 dilution using the 
commercial  Human albumin ELISA Kit (Alpha Diagnostic International) with intra-assay 
CV of 6.8 to 11.4 % and inter-assay CV of 3.5 to 6.4%. 
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Determination of sHLA-G and sHLA-I Indexes 
Fetal production of HLA-G was calculated with the following formula [38]:  
sHLA-G Index = amniotic fluid/plasma sHLA-G : amniotic fluid/plasma albumin 
where the ratio between amniotic fluid and plasma albumin concentrations represents the 
status of placental barrier.  
 
sHLA-G immunoprecipitation 
Plasma and amniotic fluids were biotynilated with 0.2 mg/mL EZ-Link Sulfo-NHS-LC-Biotin 
(Pierce)[27]. Samples were immunoprecipitated for 2 hrs at RT with anti-HLA-G MoAb 
(MEMG1, specific for HLA-G free heavy chain, or MEMG9, specific for beta2-
microglobulin conjugated HLA-G, Exbio), washed twice and incubated overnight with 
protein G-Sepharose  (Santa Cruz,) at 4°C. Samples were washed twice and resuspended in 
20ul Laemli Buffer (BioRad). 
 
Western Blot analysis 
We quantified protein concentration in immunoprecipitates by the Bradford assay (Bio-Rad 
Laboratories). Total proteins, denatured at 100 °C for 5 min, were loaded with native or 
reducing buffers in 10% TGX-Pre-cast gel (Biorad), and electroblotted  onto a PVDF 
membrane (Millipore) [39]. The membrane was incubated with a horseradish peroxidase 
(HRP)-conjugated antimouse antibody (1:5000; Amersham Biosciences,) and developed with  
ECL kit (Amersham Biosciences). Images were acquired with Geliance 600 (Perkin 
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Elmer).Human choriocarcinoma trophoblastic cells (JEG-3) were used as positive control for 
constitutive HLA-G expression [40].  
 
Statistics 
Statistical analysis was performed with Stat View software package (SAS Institute Inc).  
Since data, screened by Kolmogorov-Smirnov test, presented a normal distribution, statistical 
analyses were performed using Student’s t-test when normally distributed or  non-parametric 
Mann-Whitney U test when distribution was non-normal. Frequencies of positive samples for 
a specific variable were compared by Fisher exact test. A logistic regression analysis was 
performed to evaluate the effect of different variables. The relationship between sHLA-G 
presence and HCMV infection status was investigated by the Receiver Operating 
Characteristic (ROC) curve (Zweig and Campbell, 1993) analysis (JROCFIT software, John 
Hopkins University, Baltimore, MD, USA). 
 
Ethics 
The study was carried out according to the policies of the Ethical Committee of St. Orsola-
Malpighi University Hospital, Bologna, Italy (n. 135/2013/O/Tess), of the University of 
Ferrara, Ferrara, Italy (n. 06/2013) and the rules of the Italian Ministry of Health, Rome, Italy. 
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Results 
sHLA-I, b2M and sHLA-G levels in maternal serum samples 
We evaluated sHLA-I, b2M and sHLA-G levels in sera of 130 pregnant  (30 uninfected, 56 
with primary HCMV infection and 44 with non primary HCMV infection) and 52 non-
pregnant women.  
Detectable serum levels of classical sHLA-I (sHLA-Ia) and sHLA-G were significantly more 
frequent in pregnant women (130/130; 100%) than in  non-pregnant subjects (31/52; 59.6%) 
(p < 0.0001, Fisher exact test). b2M molecules presented a trend for fewer positive samples in 
uninfected pregnant  (11/30; 36.7%) and non-pregnant women (20/52; 38.5%) than in infected 
pregnant women (54/100; 54.0%) (p=0.14, p=0.087, respectively). 
Pregnant women showed higher levels of sHLA-Ia and sHLA-G in comparison with non-
pregnant women (sHLA-Ia: p=0.022, p=0.014; sHLA-G: p<0.001, p<0.001; Student’s t test) 
irrespective to HCMV infection (Figure 1a, b). We observed no statistical differences in 
sHLA-Ia and sHLA-G serum levels between infected and uninfected pregnant women 
(Figure 1a, b). b2M levels were slightly higher in infected pregnant women than in 
uninfected pregnant women (p=0.05) (Figure 1c). Interestingly, subdividing the subjects 
according to the maternal HCMV infection status, primary infected women presented higher 
sHLA-G concentrations than in uninfected and non primary infected women (sHLA-G: 
p<0.001, p<0.001; respectively)  (Figure 1e), with no difference in sHLA-Ia and b2M levels 
(Figure 1d, f).  sHLA-Ia, sHLA-G and b2M levels were similar  in non-pregnant women 
subdivided on the basis  HCMV seropositivity (data non shown).   
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Fetal and neonatal HCMV infection status   
Fifty-six pregnant women with primary HCMV infection underwent invasive prenatal 
diagnosis.  PCR and virus isolation gave no positive result in 39 amniotic fluid specimens and 
no congenitally infected newborns were found in this group. Two of 17 amniotic fluids from 
mothers who transmitted the virus to their fetuses/babies, were  negative both for virus 
isolation and PCR. These 2 congenitally infected babies were asymptomatic at birth and 
during subsequent monitoring confirmed normal development and the absence of late-onset 
sequelae, in agreement with literature  [8-10]. The remaining 15 amniotic fluids were positive 
for both virological tests (6x10^5 copies/mL median viral load) except one case where only 
HCVMV-DNA was detected (10^3 copies/mL).  
Overall, out of the 17 fetuses/babies congenitally HCMV infected, 5 newborns were 
asymptomatic, 11 fetuses and 1 newborn symptomatic. 
All symptomatic fetuses had HCMV positive brain with severe histological brain damage and 
cerebral necrosis. 4 of them also showed pathological neurosonographic findings  
(periventricular hyperecogenicity and ventriculomegaly). 
The only symptomatic newborn had hepatosplenomegaly, thrombocytopenia (platelet count: 
<100.000/mm
3
), alanine amniotransferase (ALT) elevation (>80U/L) at birth and developed 
sequelae with sensorineural hearing loss and mild psychomotor retardation. 
 
sHLA-I, b2M and sHLA-G levels in amniotic fluid 
We evaluated sHLA-Ia, sHLA-G and b2M levels in the amniotic fluid samples from the 56 
primary infected pregnancies: 5 from infected  asymptomatic fetuses, 12 from symptomatic 
infected fetuses and 39 from uninfected fetuses. All  amniotic fluid samples were positive for 
sHLA-Ia, sHLA-G and b2M molecules. Detectable levels of sHLA-G were significantly 
 43 
 
higher in amniotic fluids from infected symptomatic fetuses than in  infected  asymptomatic 
fetuses (p<0.001) and in uninfected fetuses (p<0.001) (Figure 2b). b2M presented slightly 
higher levels in infected symptomatic fetuses than in uninfected fetuses (p=0.042) (Figure 
2c).  We observed no statistical difference in sHLA-Ia and b2M levels in amniotic fluids from 
infected symptomatic, infected asymptomatic and uninfected fetuses (Figure 2a, c).  
 
sHLA-G concentration gradient between maternal serum and amniotic fluid 
The sHLA-G increase  in infected  symptomatic fetus prompted the  question whether sHLA-
G was produced locally in amniotic compartment or derived from maternal blood. Fetal and 
maternal compartments are mutually interconnected and several molecules are exchanged 
through the amniotic and chorionic membrane. This molecular interchange could be 
hypothesized also for HLA molecules. Therefore we evaluated the concentration gradient 
between serum samples from primary infected women and the corresponding amniotic fluids.  
A sHLA-G concentration gradient from the amniotic fluid to the maternal serum was 
observed only in infected symptomatic fetuses, while uninfected and infected asymptomatic 
fetuses presented an inverse sHLA-G gradient  (Figure 3a).  These results suggest a local 
fetal production of sHLA-G, increased only in fetuses with symptomatic HCMV infection.     
 
sHLA-G index 
The association between  fetal HCMV infection and increased fetal sHLA-G expression was 
confirmed calculating the sHLA-G index in comparison with albumin. Albumin is the most 
prevalent serum protein, it surrounds the embryo’s  and it is detected in amniotic fluids [41]. 
Fainardi et al. [38] reported the use of cerebrospinal fluid and serum albumin content to 
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evaluate sHLA-G brain production. Since both blood-brain interface and placenta are 
considered selective barriers, we applied the same concept to quantify the fetal compartment 
production of HLA-G, evaluating the relative amount of amniotic  sHLA-G and albumin 
compared with maternal serum. Any increase in the index could be ascribed to  sHLA-G 
production in the fetal compartment. Albumin levels presented a decreasing trend both in 
maternal serum and in amniotic fluid when the fetus was infected (Figure 4a, b). Higher 
sHLA-G indexes were detected  in infected symptomatic fetuses (19.45%) than  in  uninfected 
and infected  asymptomatic fetuses (p<0.001, p<0.001 respectively) (Figure 4c).   
 
sHLA-G isoforms: HLA-G5, HLA-G6 and sHLA-G1 
To discriminate between  sHLA-G1 and  soluble isoforms HLA-G5 and -G6, we analysed 
isoform distribution in  maternal sera and amniotic fluid samples. Interestingly, amniotic fluid 
is mainly characterized by sHLA-G1 isoform (Figure 5b, d), while maternal serum samples 
showed higher levels of HLA-G5/-G6 isoforms (Figure 6a, c). When the samples were 
subdivided according to fetal HCMV infection, sHLA-G1 isoform increased  in the presence 
of symptomatic fetal infection, both in sera (Figure 5c) and in amniotic fluids (Figure 5d) 
with a positive concentration gradient from the amniotic fluid to the serum.     
 
HLA-G free heavy chain analysis 
HLA-G can be expressed as b2M associated or free heavy chain (HC). Previous studies 
documented a different distribution of these two conformation at the maternal-fetus interface. 
In particular, HLA-G free HC is present on distal trophoblasts, while b2M associated 
conformation is expressed by proximal trophoblasts [42]. We evaluated the presence of HLA-
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G free-HC both in both sera  and in amniotic fluids from primary HCMV infected pregnant 
women with asymptomatic or symptomatic fetus. HLA-G free-HC was detected more 
frequently in amniotic fluids from symptomatic fetuses (Figure 6c, d). On the contrary, 
maternal sera did not present HLA-G free-HC (Figure 6a, b).   
 
sHLA-G  predictive efficacy 
We analyzed serum and amniotic fluid samples for total sHLA-G, sHLA-G1, HLA-G5 levels 
and HLA-G free HC frequencies and selected different cut-offs to be used as differentiation 
values. ROC analysis showed that serum values above 50ng/ml and amniotic values above 
30ng/ml with the highest sensitivity and specificity (Table 1), in differentiating symptomatic 
from asymptomatic congenital infections. Logistic regression analysis confirmed the 
prognostic role of serum and amniotic sHLA-G levels independently from virological 
parameters (p=0.02). The isoform with the highest predictive value was sHLA-G1 for both 
serum and amniotic samples.  
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Discussion 
Virological markers in fetal blood (DNAemia, IgM ratio) cannot  predict the prognosis of 
HCMV congenital infection [43].   
Our results show  that sHLA-G levels in maternal sera and amniotic fluids are significantly 
related to symptomatic fetal HCMV infection and  suggest a predictive role for sHLA-G in 
HCMV congenital infection, as supported by ROC analysis (Table 1). In fact, sHLA-G levels 
increased only in  symptomatic fetuses. Several evidences support a specific fetal production 
of sHLA-G: i) the concentration gradient in symptomatic infection is clearly directed from 
amniotic fluid to  maternal serum; ii) The sHLA-G indexes were significantly higher in 
infected symptomatic fetuses; iii) the different distribution of sHLA-G isoforms: shedded  
sHLA-G1 was predominant in amniotic fluids while spliced HLA-G5/-G6 isoforms were 
over-represented in the maternal sera. Interestingly, sHLA-G1 isoform increased in both 
compartments when fetal infection was symptomatic suggesting that the  sHLA-G increase in 
maternal serum had a fetal origin. These data explain why HLA-G secretion does not increase 
when mothers are infected but fetuses are not (Figure 2). Likewise,  HLA-G free HC 
increases only in amniotic fluids but not in maternal sera. These results suggest the 
opportunity for further studies, necessary  to understand the mechanisms behind the transfer 
of sHLA-G molecules from the fetus to the maternal blood, possibly involving trophoblasts 
[44]. HCMV may regulate HLA-G production by post-transcriptional events such as 
increasing mRNA stability or protein translation and controlling the secretory pathway [25-
28]. Since  HCMV transmission rate is limited to 40% of cases, it is possible that placental 
mechanisms might limit viral transmission to the fetus. Different patterns of HLA-G 
production could affect the ability to counteract HCMV infection, increasing the risk of 
symptomatic sequelae, and  increased HLA-G expression could facilitate fetal transmission 
without inducing an adequate immune cell response.  
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Our results suggest that sHLA-G, mainly sHLA-G1 isoform, might be a reliable marker for 
congenital infection. However, as the results of prenatal diagnosis might lead to irrevocable 
decisions, it is highly desirable not to base these decisions on a single marker. A combination 
of viral and biological markers may provide the best key to the reliable identification of 
fetuses at risk of congenital disease as well as fetuses with a favorable outcome. A limitation 
of our study is the small number of symptomatic cases and these data must be considered only 
investigational. However, to the best of our knowledge, this is the first observation on the 
possible use of sHLA-G as a marker to discriminate between symptomatic and asymptomatic 
HCMV congenital infection. Future studies in a larger number of fetuses should be performed 
to verify whether the combination of sHLA-G and virologic markers may have a better 
diagnostic accuracy.  
The prospective use of defined cutoffs might help to integrate the routinely used HCMV 
infection markers with sHLA-G detection in the definition of at risk fetus in clinical 
counselling. Predicting prenatal outcome has undoubted advantages: i) it will decrease the 
mother’s anxiety if the predictive factors of good outcome are present; and ii) it may 
significantly reduce the rate of unnecessary abortions. 
 
Acknowledgements: The technical expertise of Francesca Bellini from the Laboratory of 
Virology, St. Orsola-Malpighi University Hospital Bologna is greatly acknowledged. We 
thank Iva Pivanti for skilful technical assistance and Linda Marie Sartor for revision of the 
English language. 
 
 
 48 
 
References   
1 Peckham CS. Cytomegalovirus infection: congenital and neonatal disease. Scand J 
Infect 1991; 78 (suppl): 82-87. 
2 Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of 
congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007; 17: 253-76. 
3 Fowler KB, Stagno RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital 
citomegalovirus in relation to maternal antibody status. N Engl J Med 1992; 326: 663-
7. 
4 Boppana SB, Pass RF, Britt WJ, Stagno S, Alford CA. Symptomatic congenital 
cytomegalovirus infection: neonatal and mortality. Pediatr Infect Dis 1992; 11: 93-9. 
5 Lazzarotto T, Guerra B, Gabrielli L, Lanari M, Landini MP. Update on the prevention, 
diagnosis and management of cytomegalovirus infection during pregnancy. Clin 
Microbiol Infect 2011; 17:1285-93. 
6 Guerra B, Simonazzi G, Puccetti C, et al. Ultrasound prediction of symptomatic 
congenital cytomegalovirus infection. Am J Obstet Gynecol 2008; 198: 380.e1-
380.e7. 
7 Lazzarotto T, Guerra B, Lanari M, Gabrielli L, Landini MP. New advances in the 
diagnosis of congenital cytomegalovirus infection. J Clin Virol 2008, 41:192-7. 
8 Gouarin S, Gault E, Vabret A, et al. Real-time PCR quantification of human 
cytomegalovirus DNA in amniotic fluid samples from mothers with primary infection. J 
Clin Microbiol 2002; 40:1767-72. 
9 Goegebuer T, Van Meensel B, Beuselinck K, et al. Clinical predictive value of real-
time PCR quantification of human cytomegalovirus DNA in amniotic fluid samples. J 
Clin Microbiol 2009; 47: 660-5.   
 49 
 
10 Revello MG, Gerna G. Pathogenesis and prenatal diagnosis of human cytomegalovirus 
infection. J Clin Virol 2004; 29: 71-83.  
11 Lin A, Xu H, Yan W Modulation of HLA expression in human cytomegalovirus 
immune evasion. Cell Mol Immunol 2007; 4:91-8. .  
12 Yan WH, Lin A, Chen BG, Chen SY. Induction of both membrane-bound and soluble 
HLA-G expression in active human cytomegalovirus infection. J Infect Dis 2009; 
200:820-6. 
13 Gong F, Song S, Lv G, Pan Y, Zhang D, Jiang H. Human leukocyte antigen E in 
human cytomegalovirus infection: friend or foe? Acta Biochim Biophys Sin 2012; 
44:551-4.  
14 Rizzo R, Bortolotti D, Baricordi OR, Fainardi E. New insights into HLA-G and 
inflammatory diseases. Inflamm Allergy Drug Targets 2012; 11: 448-63. 
15 Rizzo R, Vercammen M, van de Velde H, Horn PA, Rebmann V. The importance of 
HLA-G expression in embryos, trophoblast cells, and embryonic stem cells. Cell Mol 
Life Sci 2011; 68: 341-52. 
16 Rizzo R, Andersen AS, Lassen MR, et al. Soluble human leukocyte antigen-G 
isoforms in maternal plasma in early and late pregnancy. Am J Reprod Immunol 2009; 
62:320-38. 
17 Fons P, Chabot S, Cartwright JE, et al. Soluble HLA-G1 inhibits angiogenesis through 
an apoptotic pathway and by direct binding to CD160 receptor expressed by 
endothelial cells. Blood 2006; 108: 2608-15. 
18  Hviid TV. HLA-G in human reproduction: aspects of genetics, function and 
pregnancy complications. Hum Reprod Update 2006; 12: 209-32. 
 50 
 
19 Fournel S, Aguerre-Girr M, Huc X, et al. Cutting edge: soluble HLA-G1 triggers 
CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with 
CD8. J Immunol  2000; 164: 6100- 04. 
20  Du L, Xiao X, Wang C, Zhang X, et al. Human leukocyte antigen-G is closely 
associated with tumor immune escape in gastric cancer by increasing local regulatory 
T cells. Cancer Sci 2011; 102: 1272-80.  
21 Marchal-Bras-Goncalves R, Rouas-Freiss N, Connan F, et al. A soluble HLA-G 
protein that inhibits natural killer cell-mediated cytotoxicity. Transplant Proc  2001; 
33: 2355-9.  
22 Ponte M, Cantoni C, Biassoni R, et al. Inhibitory receptors sensing HLA-G1 
molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and 
CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci 
USA 1999;  96: 5674–9. 
23 Rajagopalan S, Long EO. A human histocompatibility leucocyte antigen (HLA)-G-
specific receptor expressed on all natural killer cells. J Exp Med 1999;  189: 1093–9. 
24 Jun Y, Kim E, Jin M, Sung HC, Han H, Geraghty DE, Ahn K. Human 
cytomegalovirus gene products US3 and US6 down-regulate trophoblast class I MHC 
molecules. J Immunol. 2000; 164:805-11. 
25 Onno M, Pangault C, Le Friec G, Guilloux V, André P, Fauchet R. Modulation of 
HLA-G antigens expression by human cytomegalovirus: specific induction in 
activated macrophages harboring human cytomegalovirus infection. J Immunol 2000; 
164: 6426-34. 
26 Park B, Spooner E, Houser BL, Strominger JL, Ploegh HL. The HCMV membrane 
glycoprotein US10 selectively targets HLA-G for degradation. J Exp Med 2010; 
207:2033-41.  
 51 
 
27 Barel MT, Ressing M, Pizzato N, et al. Human cytomegalovirus-encoded US2 
differentially affects surface expression of MHC class I locus products and targets 
membrane-bound, but not soluble HLA-G1 for degradation. J Immunol 2003; 171: 
6757-65. 
28 Schust DJ, Tortorella D, Seebach J, Phan C, Ploegh HL. Trophoblast class I major 
histocompatibility complex (MHC) products are resistant to rapid degradation 
imposed by the human cytomegalovirus (HCMV) gene products US2 and US11. J Exp 
Med 1998; 188: 497-503. 
29 Fabbri E, Revello MG, Furione M, Zavattoni Met al. Prognostic markers of 
symptomatic congenital human cytomegalovirus infection in fetal blood. BJOG 2011; 
118: 448-56.  
30 Poláková K, Bennink JR, Yewdell JW, Bystrická M, Bandžuchová E, Russ Mild G. 
acid treatment induces cross-reactivity of 4H84 monoclonal antibody specific to 
nonclassical HLA-G antigen with classical HLA class I molecules Hum Immunol 
2003; 64: 256-64. 
31 Gabrielli L, Bonasoni MP, Santini D, et al. Congenital cytomegalovirus infection: 
patterns of fetal brain damage. Clin Microbiol Infect 2012;18: 419-27. 
32 Lanari M, Lazzarotto T, Venturi V, et al. Neonatal cytomegalovirus blood load and 
risk of sequelae in symptomatic and asymptomatic congenitally infected newborns. 
Pediatrics 2006; 117:e76-83. 
33 Lazzarotto T, Ripalti A, Bergamini G, et al. Development of a new cytomegalovirus 
(CMV) immunoglobulin M (IgM) immunoblot for detection of CMV-specific IgM. J 
Clin Microbiol 1998; 36:3337-41.  
 52 
 
34 Lazzarotto T, Gabrielli L, Foschini MP, et al. Congenital cytomegalovirus infection in 
twin pregnancies: viral load in the amniotic fluid and pregnancy outcome. Pediatrics 
2003; 112:e153-7. 
35 Rizzo R, Fuzzi B, Stignani M, et al. Soluble HLA-G molecules in follicular fluid: a 
tool for oocyte selection in IVF? J Reprod Immunol 2007; 74: 133-42.  
36 Fainardi E, Rizzo R, Melchiorri L, et al. Soluble HLA-G molecules are released as 
HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsing-
remitting multiple sclerosis. J Neuroimmunol  2007; 192: 219-25. 
37 Fainardi E, Rizzo R, Melchiorri L, et al. Intrathecal synthesis of soluble HLA-G and 
HLA-I molecules are reciprocally associated to clinical and MRI activity in patients 
with multiple sclerosis. Mult Scler  2006; 12: 2-12. 
38 Fainardi E, Rizzo R, Melchiorri L, et al. Presence of detectable levels of soluble HLA-
G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF 
solubile HLA-I and IL-10 concentrations and MRI findings. J Neuroimmunol  2003; 
142: 149-58. 
39 Rizzo R, Trentini A, Bortolotti D, et al. Matrix metalloproteinase-2 (MMP-2) 
generates soluble HLA-G1 by cell surface proteolytic shedding. Mol Cell Biochem 
2013; 381: 243-5.  
40 Polakova K, Russ G. Expression of the non classical HLA-G antigen in tumor cell 
lines is extremely restricted. Neoplasma 2000;  47: 342–48. 
41 Cho CK, Shan SJ, Winsor EJ, Diamandis EP. Proteomics analysis of human amniotic 
fluid. Mol Cell Proteomics 2007; 6: 1406-15. 
 53 
 
42 Gonen-Gross T, Goldman-Wohl D, Huppertz B, et al. Inhibitory NK receptor 
recognition of HLA-G: regulation by contact residues and by cell specific expression 
at the fetal-maternal interface. PLoS One 2010; 5: e8941.  
43 Benoist G, Salomon LJ, Mohlo M, Suarez B, Jacquemard F, Ville Y. The prognostic 
value of ultrasound abnormalities and biological parameters in blood of fetuses 
infected with cytomegalovirus. BJOG 2008; 115: 823-829. 
44 Morales PJ, Pace JL, Platt JS, Langat DK, Hunt JS. Synthesis of beta(2)-
microglobulin-free, disulphide-linked HLA-G5 homodimers in human placental 
villous cytotrophoblast cells. Immunology 2007; 122:179-88.  
 
 
Figure legends 
Figure 1. Maternal serum samples expression of a, d) sHLA-Ia; b, e) sHLA-G; and c, f) b2M 
molecules, (a-c): in non-pregnant and pregnant women, without infection and with HCMV 
actively infection, (d-f): in non-pregnant and pregnant women, without infection and with 
primary and non primary HCMV infection. p values obtained by Student’s T test and mean ± 
standard deviation are reported. 
Figure 2. Amniotc fluid samples expression of a) sHLA-Ia, b) sHLA-G and c) b2M 
molecules  according to the fetal and neonatal outcome, HCMV infection with and without 
symptoms. p values obtained by Student’s T test and mean ± standard deviation are reported. 
 54 
 
 Figure 3. sHLA-G concentration gradients calculated by: (serum concentration-amniotic 
fluid concentration) and subdivided according to the fetal/neonatal outcome, HCMV infection 
with and without symptoms. Mean ± standard deviation are reported. 
Figure 4.  Albumin expression in a) maternal serum samples and b) amniotic fluids from 
HCMV primary infected pregnancy subdivided according to the fetal/neonatal outcome, 
HCMV infection with and without symptoms. c) sHLA-G indexes obtained as reported in the 
Materials and Methods section. p values obtained by Student’s T test and mean ± standard 
deviation are reported. 
Figure 5. Maternal serum samples expression of a) HLA-G5/-G6 and c) sHLA-G1 molecules.  
Amniotc fluid samples expression of b) HLA-G5/-G6 and d) sHLA-G1 b2M molecules. 
Samples were subdivided according to the fetal/neonatal outcome, HCMV infection with and 
without symptoms. p values obtained by Student’s T test and mean ± standard deviation are 
reported. 
Figure 6. Western Blot analysis. a, b) Maternal serum samples and c, d) amniotic fluids from 
HCMV primary infected pregnancy subdivided according to the fetal/neonatal outcome, 
HCMV infection with and without symptoms, were analyzed after immunoprecipitation with 
anti-free HLA-G HC moAb (MEMG1, Exbio) or anti-b2M associated HLA-G moAb (MEM-
G9, Exbio). The positivity for HLA-G molecule was evidenced at 39kD. JEG3 cell line 
supernatants were used as positive control (M). The densitometry results are reported as 
arbitrary units. 
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 Table 1. Prognostic HLA-G marker of symptomatic congenital HCMV infection (receiver 
operator characteristics analysis) 
 
 
 
 
 
 
  Fetuses Diagnostic accuracy (%, 95%CI) 
Parameters Cutoff Sympt. Asympt. Sens. Spec.       PPV 
 
NPV 
 
Maternal 
serum 
samples 
        
         
sHLA-G 50ng/ml Above 
Below 
10 
2 
0 
5 
 
83.3 
51.6-97.4 
100 
47.9-100 
100 
68.9-100 
71.4 
29.3-95.5 
 
sHLA-G1 
 
 
HLA-G5 
 
 
HLA-G free 
heavy chain 
 
50ng/ml 
 
 
50ng/ml 
 
 
 
Above 
Below 
 
Above 
Below 
 
Presence 
Absence 
 
 
10 
2 
 
0 
12 
 
0 
12 
 
0 
5 
 
3 
2 
 
0 
5 
 
83.3 
51.6-97.4 
 
0 
0-26.7 
 
0 
0-26.7 
 
100 
47.9-100 
 
40.0 
6.5-84.6 
 
100 
47.9-100 
 
100 
68.9-100 
 
0 
0-69.5 
 
0 
 
71.4 
29.3-95.5 
 
14.3 
2.2-42.8 
 
29.4 
10.4-55.9 
 
 
Amniotic 
fluid 
        
         
sHLA-G 30ng/ml Above 
Below 
11 
1 
0 
5 
91.7 
61.5-98.6 
100 
47.9-100 
100 
71.3-100 
83.3 
36.1-97.2 
 
sHLA-G1 
 
 
HLA-G5 
 
 
HLA-G free 
heavy chain 
 
50ng/ml 
 
 
50ng/ml 
 
 
 
Above 
Below 
 
Above 
Below 
 
Presence 
Absence 
 
 
11 
1 
 
0 
12 
 
12 
0 
 
0 
5 
 
0 
5 
 
3 
2 
 
91.7 
61.5-98.6 
 
0 
0-26.7 
 
100 
73.3-100 
 
 
100 
47.9-100 
 
100 
47.9-100 
 
40 
6.4-84.6 
 
 
100 
71.3-100 
 
0 
 
 
80 
51.9-95.4 
 
83.3 
36.1-97.2 
 
29.4 
10.4-55.9 
 
100 
19.2-100 
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HLA-G induction by viruses represents an important immune-escape strategy [86]. For this 
reason, the comprehension of viral mechanisms that lead to HLA-G expression are crucial to 
counteract the infection itself. The important role played by HLA-G induction during viral 
infection was reported by many studies in different viral infections [82, 86] and also 
confirmed by our study on HLA-G expression in nasal polyposis. Sinonasal polyposis (SNP) 
is a chronic inflammatory pathology that could develop after HPV infection. Effectively, HPV 
infection is one candidate for the development of the disease for its epithelial cell trophism, 
hyperproliferative effect, and the induction of immune-modulatory molecules as HLA-G. In 
our study, we reported that HPV-11 positive SNP without concomitant allergic diseases 
(SNP-WoAD) patients presented with mHLA-G and IL-10R on epithelial cells from nasal 
polyps and showed secretion of sHLA-G and IL-10 in culture supernatants. On the contrary, 
no HLA-G expression was observed in HPV negative polyps. Our data support the crucial 
role of HLA-G expression induced by HPV in polyposis aetiopathogenesis [115 paper 
attached]. 
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Many viruses have also developed other strategies for escaping host immune surveillance, or 
example through the secretion of cytokines that affect the host cytokine network. Cytokines 
are also important in bacterial infections. The interleukin- (IL-) 10 family of cytokines and the 
related interferon (IFN) family form the larger class II cytokine family [116]. There are three 
subgroups into the IL-10 family, defined on the basis of their biological functions: IL-10, the 
IL-20 subfamily cytokines (including IL-19, IL-20, IL-22, IL-24, and IL-26), and the type III 
IFN group (IFNߣs).  
Several viruses are able to induce the expression of cellular IL-10, produced mainly by 
monocytes and, to a latter extent, by lymphocytes and, possibly, mast cells. Other viruses, 
such as the Epstein-Barr virus and hCMV, produce functional orthologs of IL-10 [114]. 
 
1.1.2 HLA-G and bacterial infections 
To date, the role of HLA-G in maintenance of bacterial infections has been poorly investigate. 
As previously shown in Figure 1, during bacterial infections the main immune escape 
mechanisms are involved in downregulate the innate immunity and it is in this scenario that 
HLA-G is used by bacteria as an immune escape mechanism [86].  
Septic shock is a condition associated to high mortality (40–50%). initially characterized by 
an important systemic inflammatory response immediately followed by an anti-inflammatory 
process that acts as negative feedback. This compensatory inhibitory response could 
subsequently worsen the condition, as nearly all immune functions are compromised [118].  It 
has been reported that the persistent HLA-G5 expression in septic shock was predictive of 
survival [119]. During sepsis, the exocytosis-mediated upregulation of ILT4 expression on 
neutrophils is inhibited, so the huge amounts of HLA-G5 found in the plasma samples of 
patients surviving sepsis may have allowed them to control neutrophil inflammatory activity 
[120]. However, soluble HLA-G concentration was not found to be predictive of the detection 
of bacteremia and sepsis in pediatric oncology patients with chemotherapy-induced febrile 
neutropenia [121]. 
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Conserning bacterial infection, I focused on the analysis of the possible role of HLA-G during 
Pseudomonas aeruginosa (P. aeruginosa) infections. P.aeruginosa is a gram negative bacteria, 
often associated with respiratory diseases, such as Cystic Fibrosis (CF) [122]. In this work, 
we performed ELISA assays and qualitative and quantitative mRNA analysis of cell lines, 
exhaled breath condensate (EBC) and plasma from CF patients and healthy controls (CTRLs) 
in order to identify if P.aeruginosa infection regulated HLA-G expression. We found lower 
HLA-G levels in plasma of CF patients that, after treatment, became undistinguishable from 
those found in CTRLs. HLA-G was higher in the EBC of CF patients and was normalized 
after antibiotic therapy only in CF patients that were free of P. aeruginosa infection. These 
data demonstered that HLA-G levels can monitor the efficacy of IV antibiotic treatment in CF 
patients and that in the CF lung microenvironment, higher expression of HLA-G is associated 
with P. aeruginosa infection suggesting that this molecule could play a role in bacterial 
immune-escape mechanisms [123 paper attached].  
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Figure 1. 
 
  
 
  
  
 
  
 
Figure 5. 
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In order to confirm the results obstained in CF patients, we investigate how P.aeruginosa 
could affect HLA-G expression. P.aeruginosa is able to produce a series of soluble molecule 
that altogether constitute the system of “Quorum sensing” (QS) [124] (Figure 3). The QS 
system is composed by two main kind of autoinducers that are crucial for the bacterial 
virulence and biofilm formation. As shown in Figure 3, the main molecules employed in the 
QS system are 3-o-C12-HLS and C4- HLS, which interact respectively with the Lasr/LasI and 
RhlR/RhlI elements [125]. By literature, it is known that QS molecules influence the host 
immune system, as for example the 3-o-C12-HSL [126-130]. The analysis of HLA-G 
membrane expression in PBMCs after exposition to biofilm forming P. aeruginosa culture 
supernatant evidenced an increase in membrane-bound HLA-G expression in monocyte 
(CD14
+
) and T (CD3
+
) cells [131 paper attached]. These data are in agreement with the 
hypothesis that quorum sensing molecule 3-o-C12-HLS production could up-regulate HLA-G 
expression (Patent n. FE2014A000005 filed on 6
th
 November 2014). Basing on these results, 
we demonstrated that 3-o-C12-HSL was an HLA-G inducer by treating different cell lines 
[131 paper attached]. The data confirmed that 3-o-C12-HSL was able to induce HLA-G 
expression particularly in monocyte U937 and Jurkat T cell lines through the CREB\p38 
phosphorylation, confirming in this way our hypotesis that P.aeruginosa can induce HLA-G 
expression during infection.  
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Figure 3. Virulence regulation of and interactions between the two AHL quorum-
sensing systems in P. aeruginosa. After a threshold concentration of 3-oxo-C12-HSL is 
produced, the 3-oxo-C12-HSL–LasR complex binds the promoter regions of multiple genes, 
activating or repressing their transcription. Among the genes upregulated by this complex 
are lasI, which enhances the production of 3-oxo-C12-HSL (autoinduction effect), and rhlR, 
which increases the production of the rhl response regulator RhlR, activating the second AHL 
pathway at an earlier stage. Virulence factors regulated by each respective receptor-ligand 
complex are detailed on the left. 
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Pseudomonas aeruginosa quorum sensing molecule N-(3-oxododecanoyl)-homoserine-L-
lactone (3-o-C12-HSL) induces HLA-G expression in human immune cells. 
 
 
 
 
Introduction 
Quorum sensing (QS) is the process through which bacterial cells communicate enabling 
unicellular populations to coordinate their response to an external stimulus as a function of 
population density, [1]. Gram negative bacteria such as Pseudomonas aeruginosa (P. 
aeruginosa) employ N-(3-oxododecanoyl)-L-homoserine lactone (OdDHL) QS signal 
molecules. P. aeruginosa is an opportunistic human pathogen responsible for causing 
infection in immune compromised individuals [2]. P. aeruginosa employs an OdDHL-
dependent QS system that via las/rhl plays a key role in controlling virulence factor 
production, biofilm maturation, swarming motility and the expression of antibiotic efflux 
pumps [3].  There is an increasing body of evidence that OdDHLs are able to interact with a 
range of mammalian cell types. In particular, they can modify function of respiratory 
epithelial cells and fibroblasts [4,5] and they interact with immune cells [6-9]. In particular, 
N-3-(oxododecanoyl)-L-homoserine lactone (3-o-C12-HSL) has the potential to modulate the 
immune system of the host. 3-o-C12-HLS has a powerful inhibitory effect on professional 
immune cells, inhibiting dendritic cell and T-cell activation [10], promoting apoptosis [11 – 
13] and inhibiting the ability of macrophage and monocytes to respond to a range of Toll-like 
receptor (TLR) agonists through disruption of NF-κB signalling [14]. Taken together, these 
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data suggest that 3-o-C12-HLS suppresses the function of key immune networks responsible 
for bacterial clearance. 
HLA-G is a non-classical Human Leukocyte Antigen (HLA) class I characterized by the 
presence of membrane bound and soluble isoforms [15]. HLA-G is involved in mechanisms 
of immune tolerance in several conditions including pregnancy, organ transplantation, 
autoimmune and inflammatory diseases by inhibiting cytolytic functions of natural killer 
cells, cytotoxic T-lymphocytes, and T-cell allo-proliferative responses [15]. Both soluble and 
membrane-bound HLA-G isoforms have similar functions and interact with specific 
inhibitory receptors (ILT-2 ILT-4) expressed by immune cells [15]. During viral infections, 
HLA-G molecules are up-regulated by the virus as a mechanism of immune-escape [16], 
inhibiting the host immune response.  
 A recent work by Glucksam-Galnoy et al. evidenced that 3-o-C12-HLS is able to modulate 
IL-10 production in macrophages [17] involving the transcriptional factors NFkB and p38. 
Since IL-10 is one of the major HLA-G inducers [18], it seems reasonable to speculate that 
also HLA-G expression could be regulated in turn by 3-o-C12-HLS. 
Moreover, a marked elevation of soluble human leukocyte antigen-G protein was observed 
during septic shock [19] and polymorphisms in exon 8 at the 3 'UTR of HLA-G gene 
(+2960IN_+3142G_+3187A haplotype) recognized septic patients with an increased risk for 
septic shock [20]. For this, it seems reasonable a possible implication of HLA-G during 
bacterial infections, with a possible dual explanation: i) immune-inhibitory mechanism 
induced by the bacteria to prevent host immune response; ii) HLA-G expression or secretion 
may reflect an appropriate and efficient response to the inflammatory process occurring 
during septic shock. 
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The objective of the present study was to determine whether 3-o-C12-HLS could modify 
HLA-G expression by immune cells, supporting the hypothesis of a direct involvement of 
bacteria in the induction of HLA-G molecules.  
 
Materials and Methods 
Cell lines and Bacteria strain 
U937 (ATCC CRL1593.2) and THP-1 (ATCC TIB202) monocyte cell lines, Jurkat (ATCC 
TIB152) T-cell line and 721.221 (ATCC CRL1885) B-cell line were grown in RPMI 1640 
(Gibco) added with 10% FBS, 10% Hepes Buffer, 5% peniciline\strepatamicin at 37°C with 
5% of CO2.  
P.aeruginosa (ATCC BAA-47) PAO1 strain was grown in Tryptic Soy broth (Sigma) at 37°C 
for supernatant collection. 
 
Peripheral blood mononuclear cell purification 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood of 10 control 
subjects by Ficoll gradient (Cederlane, Hornby, Ontario, Canada) and resuspended in RPMI 
medium (EuroClone, Milano, Italy)  with 10% FCS, 100U/ml penicillin and 100 U/ml 
streptomycin (Sigma-Aldrich, S.Louis, MO, USA). 
 
Cell treatments 
The cells were treated with 3-o-C12-HSL (Sigma-Aldrich) at the concentrations of 10, 25 and 
50uM, suggested by literature [17], at different time points and then analyzed. 
For the inhibitory experiments, Fc receptors were first blocked using human serum, and cells 
were incubated for 30 min at 37°C with a final concentration of 10 μg/ml isotype control 
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monoclonal antibody (moAb) or blocking anti-IL-10 (Biolegend) or anti-ILT2 (Becton 
Dickinson) monoclonal antibodies (moAbs) prior to use. 
To induce monocyte differentiation and activation, 5x10
4
  cells were seeded in 500μl 
complete medium containing 160 nM PMA (Sigma Chemical). Cells were then analyzed by 
flow cytometry. 
 
Cytometric analysis  
For flow cytometric analysis, cells (10
6
) were washed and incubated for 30 minutes on ice in 
100 μl of Phosphate Buffered Saline (PBS) containing 1% FBS, 10 mM sodium azide plus 
appropriately diluted fluorescent moAb. After two washes with cold washing buffer, cells 
were then washed, fixed in 2% formaldehyde, and analyzed by flow cytometry with a 
FACSVantage flow cytometer (Becton Dickinson, San Jose, CA, USA) using standard 
settings and CellQuest software (Becton Dickinson, San Jose, CA, USA) for data analysis. 
The membrane bound HLA-G antigens were detected by anti-HLA-G FITC moAb 
(87GExbio, Praha, Czech Republic), HLA class I molecules were stained by HC10-FITC 
moAb (kind gift of Prof. Fabio Malavasi). Anti-isotype controls (Exbio, Praha, Czech 
Republic) were performed. PBMCs were analyzed using anti-CD3-PerCP, anti-CD14-PE, 
anti-CD45-PE, anti-CD56-PE (BD) moAbs. 
Cell cycle was analyzed by Propidium Iodide (PI) staining. Cells were resuspended cells in 
500 µl PI/Triton X-100 staining solution [(0. 1 % (v/v) Triton X-100 (Sigma) in PBS,  2 mg 
DNAse-free RNAse A (Sigma), 0.40 ml of 500 µg/ml PI (Roche)], incubated for 30 minutes 
at RT and analyzed by flow cytometry. 
Annexin-V staining (Annexin V-FITC apoptosis detection kit;  Bender MedSystem)  was 
used to measure the apoptosis. The cells were resuspended in 1x binding buffer [10 mmol/L 
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HEPES (pH 7.4), 140 mmol/L NaCl, 2.5 mmol/L CaCl2] for analysis. Cells were stained with 
Annexin V-FITC to reveal apoptosis and with propidium iodide to detect dead cells. 
Monocyte differentiation was evaluated with anti CD11b-FITC and anti-CD14-PE (BD) 
moAbs. 
 
Immunofluorescence microscopy 
For immunofluorescence microscopy, cells (10
6
) were washed and incubated for 30 minutes 
on ice in 100 μl of Phosphate Buffered Saline (PBS) containing 1% FBS, 10 mM sodium 
azide plus appropriately diluted fluorescent mAb. After two washes with cold washing buffer, 
cells were then washed, fixed in 2% formaldehyde, and analyzed by fluorescence microscopy. 
Membrane bounded HLA-G (mHLA-G) was detected by direct immunofluorescence using 
the anti-HLA-G FITC moAb (MEM-G9, Exbio, Praha, Czech Republic), while 
CREB\pCREB (Immulogical Sciences) and p38\pp38 (SantaCruz) were detected by indirect 
immunofluorescence with the secondary antibody Goat anti-Mouse FITC (Dako). 
 
ELISA 
Soluble HLA-G (sHLA-G) levels in cell culture supernatants were measured by enzyme-
linked immunosorbent assay (ELISA) using as capture antibody the MoAb MEM-G9 (Exbio, 
Praha, Czech Republic), which recognizes the HLA-G molecule in ȕ2-microglobulin 
associated form. The intra-assay coefficient of variation (CV) was 1.4% and the inter-assay 
CV was 4.0%. The limit of sensitivity was 1.0 ng/ml [21].  
IL-10 levels were analyzed using Human IL10 ELISA detection kit (EBioscience).  
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MTT cell viability assay 
100ul of cells at the density of 1x10
6
\ml were seaded into 96-well plates and treated with 3o-
C12-HSL (10uM and 25uM) for 6, 12 and 24 hours (hrs). After incubation, 10ul of MTT 
(Sigma-Aldrich) for 4 hours at 37°C. Cells were then lisate by adding 100ul of MTT solvent. 
Plates were then read at 570nm for viability evaluation using ELISA-reader (Victor, Perkin-
Elmer). 
 
mRNA preparation  
Total cellular RNA was prepared from each cell cultures with TRIzol reagent (Life 
Technologies, NY, USA).
 
The RNA samples were digested with DNase. The quality and 
quantity of RNA samples were assessed by a 1%  agarose gel electrophoresis, followed by 
ethidium bromide staining. These mRNA samples were immediately used for cDNA synthesis 
or stored frozen at -80° C until use. 
 
RealTime PCR 
To analyze the presence of HLA-G mRNA, 2 ug mRNA were reverse transcribed for each 
sample using SuperScript™ First-Strand Synthesis System (Invitrogen, San Giuliano 
Milanese, MI, Italy) according to manufacturer’s instructions. The primers and the detection 
probe for HLA-G gene expression analysis were: forward primer HLAG-F (5’-
CCCACCATCCCCATCATG-3’); reverse primer HLA-G-R (5’-
CCAGTGACTACAGCTGCAAGGA-3’) and the MGB probe (5’-
TATCGTTGCTGGCCTGG-FAM-3’) (Applied Biosystem) [22]. Fold expression changes 
were determined by the 2- CT method. Amplification was performed with 100ng of RNA 
converted into cDNA, TaqMan 2X Universal PCR Master Mix in a final volume of 50ul  
(Applied Biosystem) following this protocol: 2 minutes at 50°C for AmpErase UNG 
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activation, 20 seconds at 95°C for initial denaturation followed by 40 cycles 20 second at 
95°C and 60 seconds at 60°C for amplification.  All reactions were performed in triplicate 
 
Reporter Constructs and Expression Vectors 
Luciferase reporter plasmids were generated by cloning genomic promoter fragments into 
pGL3-Basic (Promega, Madison, WI). These constructs contain, respectively, a 1438-bp 
promoter fragment ofHLA-G (pGL3-G1500), and a 269-bp AspI-AhaIIHLA-B7 promoter 
fragment (pGL3-HLA-B) (kind gift of Prof. Sam JP Gobin) [23]. All inserts were verified by 
sequence analysis. 
The Renilla luciferase control plasmid pRL-actin was used as transfection efficiency control.  
 
Transient Transfection 
721.221 cells were transfected by Amaxa Nucleofector technology (Lonza) with a DNA 
precipitate of 1 μg of pGL3 reporter plasmid, 1 or 0.5 μg of expression vector, and 0.1 μg 
of Renilla luciferase control plasmid (pRL-actin) per well. Luciferase activity was determined 
using a luminometer (Victor, Perkin Elmer) and corrected for transfection efficiency with 
the Renilla luciferase activity values. 
 
Statistical analysis 
Since the values presented a normal distribution (Kolmogorov-Smirnov test) , the differences 
were evaluated by the Student T test using Stat View software (SAS Institute Inc, Cary, NC, 
USA). p value was considered to be statistically significant when <0.05. 
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Results 
P. aeruginosa culture supernatant induces HLA-G
+
CD3
+
 and HLA-G
+
CD14
+
 cells. 
To evaluate the induction of HLA-G molecules by P. aeruginosa in human immune cells, we 
exposed peripheral blood mononuclear cells (PBMCs) from 10 control subjects to the culture 
supernatants (SN) of biofilm-forming P. aeruginosa. PBMCs were negative for HLA-G 
staining before the treatment. After 6 hrs of incubation with 25ul of P. aeruginosa SN, we 
observed a 1.5±0.5% (mean±SD) of CD14
+
HLA-G
+
 cells (p=0.002, Student T test) (Figure1a, 
black histogram), that increased to the 8.0±0.4% after 12hrs (p<0.0001) and returned to 
1.8±0.2% (p=0.001) after 24hrs of treatment. 10uL and 50uL P. aeruginosa SN were able to 
induce CD14
+
HLA-G
+
 cells after 12hrs (3.4±0.5% and 3.9±0.6% respectively) (p<0.001), that 
decreased to 1.9±0.2% and 1.4±0.3% after 24hrs (p=0.001). The induction of CD3
+
HLA-G
+
 
cells was observed after 12hrs incubation with 25uL (2.5±0.3%) (p<0.001) and 50uL 
(2.3±0.3%) of P. aeruginosa SN (Figure 1a, white histogram) and decreased to 1.2±0.1% and 
1.75±0.2% after 24hrs.  Both CD3
+
 and CD14
+
 cells presented the highest mHLA-G 
induction after 12hrs incubation with 25ul P. aeruginosa SN (2.5±0.3% CD3
+
HLA-G
+
 and 
8.0±0.4% CD14
+
HLA-G
+
 cells) (Figure 1a). The decrease in HLA-G expression after 24hrs 
incubation sustains a time-dependent induction of HLA-G expression. As a confirm, we 
performed a RealTime PCR quantification of HLA-G mRNA in PBMCs after P. aeruginosa 
SN treatment. We observed a 4 folds increase in HLA-G mRNA transcription 6hrs after the 
incubation with P. aeruginosa SN (Figure 1b) (p<0.0001), that reached a 6 folds increase 
after 12hrs treatment (p<0.001) but was lost after 24hrs. The expression of HLA-G molecules 
was evaluated also on the surface of B and Natural killer cells, however we found no HLA-G 
induction (data non shown).    
We are aware that P. aeruginosa SN could contain several molecules able to modify HLA-G 
expression. For this, we performed a literature meta-analysis to identify the molecule with the 
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highest probability to be an immune-modifier,  We selected 3-o-C12-HSL, that has the 
potential to modulate the immune response of monocytes and T cells [13].   
 
P. aeruginosa  3-o-C12-HSL effect on monocyte and T cell viability. 
First of all, we verified if 3-o-C12-HSL treatment could affect monocyte and T cell viability. 
We used monocyte THP-1 and U937 and T- (Jurkat) cell lines to standardize the experiments. 
We treated the cells with 10, 25 or 50 uM of 3-o-C12-HSL [17] for 6, 12 and 24 hours. After 
the treatments, cell viability was evaluated by MTT assay. The major effect on cell viability 
was observed in U937 cells with all the concentrations of 3-o-C12-HSL. In fact, we observed 
a 40% decrease in cell viability after 12hrs of incubation with all the concentrations of 3-o-
C12-HSL (Figure 2a). Interestingly, U937 cells reconstituted their viability after 24hrs of 
incubation. On the contrary, neither the monocyte cell line THP-1 (Figure 2b), nor Jurkat 
(Figure 2c) cell line showed any significant decrease in cell viability.  
On the basis of this results, we selected to work with the lowest 3-o-C12-HSL concentrations 
(10 and 25uM) and 24 hrs of incubation. 
 
P. aeruginosa  3-o-C12-HSL induces HLA-G expression in human monocyte and T cells. 
To be sure that 3-o-C12-HSL  is able to induce HLA-G transcription and transduction, we 
treated U937 monocyte cell line with 3-o-C12-HSL for 24hrs and evaluated HLA-G mRNA 
and protein expression. We observed an increased production of HLA-G specific mRNA 
(Figure 3a) that followed a dose-dependent effect, with 10uM 3-o-C12-HSL inducing a 3 
folds increase of HLA-G mRNA and 25uM  inducing a 6 folds increase in comparison with 
untreated cells (p<0.001; Student t test). Membrane HLA-G expression acts similarly, with an 
increase of 10% after 10uM and 30% after 25uM  3-o-C12-HSL treatment (Figure 3b, c). 
Jurkat cells presented a 5 and 7 folds increase of HLA-G
+
 cells with 10uM and 25uM 
 113 
 
respectively (Figure 3d). On the contrary, THP1 cells presented a lower increase of HLA-G 
expression after 3-o-C12-HSL treatment (Figure 3e). These results suggest the presence of a 
specific pathway of HLA-G induction following 3-o-C12-HSL treatment that presents 
differences between cells. 
 
P. aeruginosa  3-o-C12-HSL did not induce classical HLA-I expression in human 
monocyte U937 cell line. 
To be sure that the effect of 3-o-C12-HSL treatment is HLA-G specific, we treated U937 cell 
line with 3-o-C12-HSL for 24hrs and evaluated classical HLA-I expression, by means of HC-
10 moAb, that is recognized not to bind HLA-G molecules [24]. We observed no 
modifications in classical HLA-I molecule expression in U937 cells (Figure 4a, left panel), 
while HLA-G was up-modulated (Figure 4a, right panel). On the basis of these results, we 
sustain that 3-o-C12-HSL effect is specific for HLA-G. To account the direct effect of 3-o-
C12-HSL on HLA-G gene promoter, we transfected 721.221 cell line (classical and non 
classical HLA-I negative cells) with HLA-G or HLA-B promoters [23]. These cells were 
treated with 3-o-C12-HSL and luciferase assay was performed. We observed an increased 
activation of HLA-G promoter after 3-o-C12-HSL treatment. In particular, the promoter 
activation was dose-dependent with an increased activation of 21 and 39 folds with 10uM and 
25uM respectively (Figure 4b, black histograms). On the contrary, HLA-B promoter was not 
affected by 3-o-C12-HSL treatment (Figure 4b, gray histograms). These data sustain a 
specific effect of 3-o-C12-HSL on HLA-G promoter. 
Because of the characteristics of 3-o-C12-HSL, that can act via transcription factors [14, 25] 
and IL-10 expression [17], we hypothesized two possible pathways for HLA-G induction: i) 
via IL-10, as one of the main modulator of HLA-G expression [18] or ii) direct HLA-G 
induction via transcriptional factors. 
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P. aeruginosa  3-o-C12-HSL enhances HLA-G expression via IL-10 induction. 
Since IL-10 is one of the major HLA-G inducers [18], and it is known that 3-o-C12-HSL is 
able to induce IL-10 expression in macrophages [17], we evaluated the possible implication of 
this cytokine in 3-o-C12-HSL/HLA-G pathway. We analyzed the levels of IL-10 and sHLA-
G expression in Jurkat, U937 and THP1cell culture supernatants after 3-o-C12-HSL 
treatment. We observed an increased secretion of IL-10 already 6hrs after 3-o-C12-HSL 
addition in both Jurkat and U937 cells (Figure 5a, white histograms) that could account for 
the sHLA-G increase that appeared to be significant after 12hrs treatment (Figure 5a, gray 
histograms). On the contrary, THP1 presented no IL-10 induction after 3-o-C12-HSL 
treatment (Figure 5a), that could account for the absence of HLA-G up-regulation in THP1 
cells.  To evaluate the role of IL-10, we pre-treated U937 cells with anti-IL-10 moAb and 
observed the reduction of HLA-G secretion in 3-o-C12-HSL treated U937 cell culture 
supernatants (Figure 6, gray histograms). It is to note that this blocking treatment was not able 
to completely inhibit HLA-G expression, even increasing anti-IL-10 moAb concentrations 
(data non shown), demonstrating that IL-10 is only one of the mechanisms used by 3-o-C12-
HSL to induce HLA-G expression.  
 
P. aeruginosa  3-o-C12-HSL enhances HLA-G expression via p38-CREB transcription 
factors. 
Since 3-o-C12-HSL is known to modify transduction pathways [25], in particular inducing 
p38, a mitogen-activated protein kinase (MAPK) that phosporylates and activates the cAMP-
response-element-binding protein (CREB) [26], a transcription factor that regulates HLA-G 
gene expression [23],we evaluated the phosphorylation status of p38 and CREB after 3 -o-
C12-HSL treatment in U937 cells. We observed a clear increase in total p38 and 
phosphorylated p38 after 15 minutes (Figure 7a) and  an increased phosphorylation of CREB 
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after 30 minutes of 10 uM  3-o-C12-HSL treatment  (Figure 7b). On the contrary, THP1 cells 
did not present p38/CREB phosphorylation (Figure 7c, d). These data suggest the induction of 
p38 and CREB phosphorylation by 3-o-C12-HSL as responsible for the direct effect of this 
QS molecule on HLA-G expression [23].    
 
P. aeruginosa  3-o-C12-HSL enhanced HLA-G expression affects U937 cell viability via 
ILT2 receptor. 
If we take into consideration the results on cell viability (Figure 2a, b, c), we observe an 
intriguing result. In particular, we observed a decrease in cell viability only in U937 cells 
(Figure 2a) and not in THP1 and Jurkat cells (Figure 2b, c) after 6 and 12hrs 3-o-C12-HSL 
treatment.  We can speculate that MTT assay could reveal cytotoxicity (loss of viable cells) or 
cytostatic activity (shift from proliferation to quiescence)  of 3-o-C12-HSL treatment. For 
this, we analysed U937 cells with Anexin-V staining to account cell apoptosis and necrosis 
and PI staining for cell cycle evaluation. Anexin-V staining failed to reveal cell 
apoptosis/necrosis after 12hrs 3-o-C12-HSL treatments (Figure 8a). On the contrary, the 
analysis of cell cycle showed that the treatment with 3-o-C12-HSL for 12hrs blocked a 62% 
of cells in a G0/G1 stage in comparison with the 20% of G0/G1 cells before the treatment 
(Figure 8a). Since decreased cell division could be  associated with differentiation, we 
evaluated U937 phenotype. Flow cytometry was carried out to monitor two surface proteins 
characteristic of U937: 1) CD14, marker for both monocyte and macrophage, involved in LPS 
recognition and contact with TLR4 receptor; 2) CD11b, macrophage marker, involved in 
phagocytosis of bacteria. CD14 expression was maintained after 12hrs of 3-o-C12-HSL 
treatment (Figure 9a), yielding the characteristics of monocyte-like cell type. CD11b 
expression was increased only after PMA treatment, indicating macrophage-like 
differentiation, meanwhile no CD11b induction was observed after 12hrs 3-o-C12-HSL 
 116 
 
treatment (Figure 9b). Since we observed that 3-o-C12-HSL induces HLA-G expression, we 
could speculate that the interaction with its ligands could affect cell viability. We tested U937, 
THP1 and Jurkat cells for ILT2 expression and we observed the presence of this receptor only 
in U937 cells (Figure 9c, d, e). ILT2 is a surface receptor expressed by different immune 
system cells, including monocytes, that is able to bind HLA-G and modify monocyte status 
[27]. We performed again the experiments on U937 cells in the presence of anti-ILT2 moAb. 
Interesting, we observed  no decrease in U937 viability when the experiments were performed 
with anti-ILT2 antibody (Figure 9f). These data suggest that the induction of HLA-G by 3-o-
C12-HSL could act on ILT2 explaining the cytostatic activity on U937 cells. 
 
Proposed pathways 
Figure 10 illustrates a potential network that might operate in the presence of 3-o-C12-HS. It 
incorporates previous findings and the observations made in this study. In this network, 3-o-
C12-HS activates HLA-G expression via p38 and CREB phosphorylation [23] and IL-10 
induction, that acts in a feed-back loop pathway of HLA-G induction [18]. In the presence of 
ILT2 expression, the interaction with HLA-G molecules could modify cell activity, promoting 
a resting status.  
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Discussion 
3-o-C12-HLS is a bacterial quorum sensing molecule that coordinates bacteria growth and 
virulence in a cell density-dependent manner [1]. Furthermore, different studies have already 
reported the ability of 3-o-C12-HLS in regulating both pro- and anti-inflammatory cytokines 
production by host cells [4-14; 27]. 
Even more evidences suggested that 3-o-C12-HLS plays a critical role not only in inter-
bacterial communication, but also in inter-kingdom signaling. In fact, 3-o-C12-HLS can 
interact with mammalian cells, including immune cells [4-14; 25]. In particular, 3-o-C12-HLS 
exhibit modulatory effect on monocytes [28] inducing changes in mRNA transcription. Since 
HLA-G is a key molecule in the immune system switch-off [15] a the aim of our study was to 
investigate whether 3-o-C12-HLS induced HLA-G modification in immune cells. 
In this research we report that 3-o-C12-HLS affects HLA-G production in monocyte and T 
cells, involving the CREB\p38 and IL-10 pathways. 
The analysis of HLA-G membrane expression in PBMCs after exposition to biofilm forming 
P. aeruginosa culture supernatant evidenced an increase in membrane-bound HLA-G 
expression in monocyte (CD14
+
) and T (CD3
+
) cells. These data are in agreement with the 
hypothesis that quorum sensing molecule 3-o-C12-HLS production could up-regulate HLA-G 
expression.  
The induction of HLA-G by 3-o-C12-HLS was confirmed in monocyte U937 and Jurkat T 
cell  lines. As a proof of concept, THP1 cell line did not present HLA-G expression nor IL-10 
induction and CREB\p38 phosphorylation after 3-o-C12-HLS treatment, supporting the 
existence of a network between IL-10\CREB\p38 phosphorylation and HLA-G. The 
implication of ILT2 receptor expression on the cytostatic effect  of 3-o-C12-HLS on U937 
cells is a direct proof of the functional activity of the HLA-G molecules induced by 3-o-C12-
HLS. In particular, they sustain the immunosuppressive properties of HLA-G molecules and 
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could explain the effect of in vivo 3-o-C12-HLS production by bacteria, as an efficient 
mechanism to modulate host immune response via HLA-G. On the other hand, HLA-G 
expression could be a response to the inflammatory process occurring during microbial 
infection, reflecting an appropriate and effective feedback control of inflammatory process. 
On the basis of our knowledge, we propose a dual role for HLA-G induction during bacterial 
infections, as an immune escape factor for the bacteria and a rescue mechanism for the host. 
In particular, bacteria could induce cell release of sHLA-G in peripheral blood leading to the 
down-regulation of chemokine receptors on T lymphocytes and NK cells, that can affect the 
migration of these cell populations toward inflamed tissues, leading to immune escape of 
bacteria [29]. The loss of balanced sHLA-G levels may cause a the activation of  immune 
effector cells  and their migration to the inflamed tissues, contributing to the exacerbation of 
bacterial infection. 
In conclusion, we presented for the first time the effect of 3-o-C12-HSL treatment on HLA-G 
induction. As a future perspective, it will be of importance to recognize the cell types 
responsive to 3-o-C12-HSL treatment. Using 3-o-C12-HSL to induce HLA-G expression 
could also be useful for clinical purposes where a natural tolerance is beneficial instead of the 
use of immune-suppressive drugs, as in transplantation and pregnancy 
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Figure legends 
 
Figure 1. a) Membrane HLA-G expression in PBMCs from 10 healthy subjects. Cells were 
treated with 10, 25, 50 uL P. aeruginosa culture supernatnats (SN) for 6, 12 and 24hrs. CD3
+
 
(white hystogram) and CD14
+
 (black histogram) cell results are reported. b) HLA-G mRNA 
expression analysis in PBMCs after 6, 12 and 24hrs treatment with 25 uL P. aeruginosa 
culture supernatnats (SN). Mean ± standrd deviation (SD) is reported. ** Significant p value 
<0.05 obtained by Student T test.   
 
 123 
 
 
Figure 2. MTT cell viability assay. Cells were treated with 10, 25 and 50uM 3-o-C12-HSL 
for 6 (white histogram), 12 (gray histogram) or 24 (black histogram) hrs. a) U937 cell line; b) 
THP-1 cell line; c) Jurkat cell line. Mean ± standrd deviation (SD) is reported. ** Significant 
p value <0.05 obtained by Student T test.   
 
Figure 3. a) HLA-G mRNA and membrane HLA-G expression, evaluated by b) flow 
cytometry (87G-FITC moAb) and c) immunofluorescence (MEM-G9 moAb) in U937 cell 
lines. Membrane HLA-G expression, evaluated by b) flow cytometry (87G-FITC moAb) in d) 
Jurkat and e) THP1 cell lines. Cells were treated with 10 and 25uM 3-o-C12-HSL for 24hrs. 
Mean ± standrd deviation (SD) is reported. ** Significant p value <0.05 obtained by Student 
T test.   
 
Figure 4. a) Membrane HLA-G (left panels) and classical HLA-I (right panels) expression in 
U937 cell line. Cells were treated with 10 and 25uM 3-o-C12-HSL for 24hrs. The percentage 
of HLA-G
+
 and HLA-I
+
 cells are reported. b) Luciferase assay: HLA-B (gray histogram) and 
HLA-G (black histogram) promoter activation analysis in 721.221 transfected cell lines after 
treatment with 10 and 25uM 3-o-C12-HSL for 24 hrs. Mean ± standrd deviation (SD) is 
reported. ** Significant p value <0.05 obtained by Student T test.   
 
Figure 5.  a) IL-10 and b) sHLA-G levels in Jurkat, U937 and THP1 cell culture supernatants. 
Cells were treated with 10 and 25uM 3-o-C12-HSL for 6 (white histogram), 12 (gray 
histogram), 24 (black histogram) hrs. Mean ± standrd deviation (SD) is reported. ** 
Significant p value <0.05 obtained by Student T test.   
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Figure 6. sHLA-G levels in cell culture supernatants of U937 cells with  anti-IL-10 or anti-
isotype moAb treatment and addition of 10 or 25uM 3-o-C12-HSL for 24hrs. Mean ± SD is 
reported. ** Significant p value <0.05 obtained by Student T test.   
 
Figure 7. Intracellular pathway activation analysis in U937 and THP1 cell lines. U93 and 
THP1 cells were treated with 25uM 3-o-C12-HSL . Protein analysis and phosphorilation 
status was performed by Immunofluorescence for: a, c) total and phoshorilated p38,b, d) total 
and phosphorilated CREB Here are reported the most representative results for p38\pp38 and 
CREB\pCREB at 0 and 30 seconds of 25uM 3-o-C12-HSL treatment. 
 
Figure 8. a) Annexin-V staining of U937 cells treated with 10, 25 and 50uM 3-o-C12-HSL 
for 24hrs. The percentage of Annexin V positive cells is reported. b) and c) Propidium Iodide 
(PI) staining. For cell cycle analysis in U937 cells treated with 25 M 3-o-C12-HSL for 24hrs. 
The percentage of cell in each cell cycle stage are reported. Here are reported the most 
representative results.  
  
Figure 9. a) Membrane CD14 and CD11b expression was evaluated by flow cytometry in 
U937 cells treated with PMA or with 10 and 25uM 3-o-C12-HSL for 12hrs. Fold increase in 
comparison with basal expression is reported. ILT2 expression on b) U937, c) THP1, d) 
Jurkat cells. Here are reported the most representative results. e) MTT cell viability assay on 
U937 cells after  10 or25uM 3-o-C12-HSL treatment for 12hrs in presence of anti-ILT2 
moAb (gray histogram) or anti-isotype moAb (black histogram). Mean ± SD is reported. ** 
Significant p value <0.05 obtained by Student T test.   
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Figure 10. Hypothesis of 3-o-C12-HSL effects on HLA-G induction. We suggest the 
implication of p38 and CREB phosphorylation and IL-10 induction, that acts in a feed-back 
loop pathway of HLA-G induction. In the presence of ILT2 expression, the interaction with 
HLA-G molecules could modify cell activity, promoting a resting status (G0/G1 cell cycle 
stage).  
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1.2 HLA-G in autoimmune and inflammatory diseases 
Inflammation is a localized protective reaction to different kind of injury and/or infections. 
The characteristic signs of inflammation include pain, heat, redness, swelling and loss of 
function that result from dilation of the blood vessels leading to an increased blood supply 
and intercellular spaces, movement of leukocytes, protein and fluids into the inflamed 
regions. Inflammatory response could be subdivided into: i) acute inflammation, with a rapid 
onset and a short duration. It is considered the main defense mechanism against bacteria, virus 
and parasites. It is characterized by the exudation of fluids and plasma proteins and the 
migration of leukocytes, most notably neutrophils into the injured area; ii) chronic 
inflammation, with a more prolonged duration and the presence of fibrosis and tissue 
necrosis. This persistent chronic inflammation facilitates the development of degenerative and 
autoimmune diseases such as rheumatological diseases, atherosclerosis, heart diseases, 
asthma, multiple sclerosis (MS), diabetes, inflammatory bowel diseases (IBD) [132,133], 
because of the persistent immune cell reactivity and cytokine secretion. The immune cell 
modulation due to the interacion between anti-inflammatory factors and immune cells and 
trascription elements plays a crucial role in  the regulation of a chronic inflammation. One of 
these anti-inflammatory components is suggested to be HLA-G. 
Given the immunomodulatory nature of HLA-G molecule, it could be considered a good 
reference parameter for prevention, diagnosis and treatment in autoimmune and inflammatory 
diseases.During my PhD period I investigated HLA-G in different pathologies characterized 
by a dysregulation in host immune system in which HLA-G plays a central role [79-82 papers 
attached, 83]. 
 
1.2.1 HLA-G in rheumatic diseases 
More than 100 pathologies are generally described as Rheumatic disease referring to 
conditions that affect the joints (rheumatoid arthritis), connective tissues (scleroderma, 
systemic lupus erythematosus) and vessels (vasculitis). Rheumatic diseases are inflammatory 
and autoimmune diseases, that are the second most common cause of disability after 
musculoskeletal injuries. Rheumatoid arthritis (RA) (OMIM, #180300) is an autoimmune 
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disease caused by the attack of the immune system to synovial cells. RA is characterized by 
inflammation, pain and stiffness in the joints that can lead to a loss of function. Both genetic 
and environmental factors may contribute to develop the disease. Gene expression profiles 
(GEPs) in bone marrow-derived RA mononuclear cells [134] reported 1,910 down-regulated 
and 764 up-regulated gene, which include the HLA-G gene. In fact, many groups investigated 
the role of HLA-G in RA, underlining the importance of both sHLA-G and HLA-G 
polymorphisms in the disease course and treatment response [45, 135]. The role of HLA-G 
polymorphisms, and in particular the HLA-G 14bpINS/DEL polymorphism, has also been 
evaluated for RA susceptibility and for its use as marker for RA therapy. The most common 
therapy used in the treatment of RA patient is based on Methotrexate (MTX), a disease-
modifying anti-rheumaticdrug (DMARD). MTX incresed IL-10 production in RA patients 
that exhibit a better therapeutic response [136] and is able to enhance HLA-G secretion by 
peripheral blood mononuclear cells [12]. Interestingly, RA patient with good response to 
MTX also showed an increased frequency of the 14bpDEL/DEL [45], with a possible 
implication in the control of immune activation. It must be underlined, however, that 
contrasting results have been obtained [137, 138], possibly due to a different dosage of MTX, 
a different cut-off value for RA therapy response assessment.  
Concernig sHLA-G levels, protein concentration in serum is significantly lower in RA 
patients [137] than in controls. This low sHLA-G concentration could contribute to develope 
the disease leading to a chronic activation of inflammatory cells. The evaluation of sHLA-G 
molecules at the specific inflammation site of the synovia reported higher levels of sHLA-G 
in RA patients [139]. The release of HLA-G in the inflamed synovium may be due to the 
recruitment of activated HLA-G positive immune cells and the local production by activated 
synovial fibroblasts [140] that could interact with immune inhibitory receptors and maintain a 
chronic inflammatory response. These data suggest that there is a different production of 
HLA-G molecules on the basis of the local and systemic environments, characterized by 
different molecular factors and cell types. Interestingly, the role of HLA-G molecules in RA 
was confirmed by a recent work. The authors used an intracutaneous treatment of HLA-G 
monomer or dimer molecules in collagen induced arthritis model mice. The treatment with 
these molecules produced excellent anti-inflammatory effects with a single, local 
administration [141]. Notably, the dimer exhibited higher immunosuppressive effects than the 
monomer due to the higher dimer affinity for PIR-B, the mouse homolog of the LILRBs. 
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Basing on these data, we investigated the possible role of HLA-G molecules as biomarkers 
for RA treatment in a follow-up study [142 paper attached]. Twenty-three early RA (ERA) 
patients were analyzed during a 12mo follow-up disease treatment for sHLA-G levels in 
plasma samples, membrane HLA-G (mHLA-G) and ILT2 expression on peripheral blood 
CD14 positive cells, and typed for HLA-G 14bp DEL/INS polymorphism. Interestingly, the 
results showed that ERA patients with low sHLA-G and membrane HLA-G expression 
suffered a more severe disease. In fact, sHLA-G levels inversely correlated with DAS28 and 
ultrasonographic power Doppler scores, used to define the severity and progression of the 
disease. Surprisingly, sHLA-G up-modulation is already evident after 3 mo of DMARDs 
therapy, while a significant reduction in tumor necrosis factor-α levels is evident after 9 mo 
therapy. At this point of therapy a clear amelioration of the disease is evident, with a high 
specificity for HLA-G detection in EA condition. Moreover, the implication of the HLA-G 
14bp INS/DEL polymorphism is confirmed as patients that showed a significantly improved 
disease status were characterized by the presence of the DEL allele. 
This result corrobores the prognostic and therapeutic value of HLA-G in RA. In fact, 
considering al the different studies on HLA-G in RA, it seems that HLA-G molecule 
evaluation can help to predict the course of the disease [143 paper attached] . 
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1.2.2 HLA-G in central nervous system diseases 
The central nervous system (CNS) represent an immune-privileged compartment that 
maintains an adaptable immune surveillance system. Dysregulated immune function within 
the CNS may lead to the development of brain tumor growth, and consitent immune 
activation results in excessive inflammation. 
Multiple sclerosis (MS) is the prototypic autoimmune disease of the CNS characterized by 
chronic inflammatory demyelination and neurodegeneration of unidentified origin [144]. MS 
typically occurs in young adults and manifests in women twice as frequently as in men with 
neurological symptoms and signs, called relapses, which are usually disseminated in space 
and time [145]. MS onset could be distinguished in: i) the relapsing–remitting (RR) form, that 
affects about the 80% of MS patients followed by ii) a secondary progressive (SP) course that 
arises after years and iii) a primary progressive (PP) forma in approximately the 20% of MS 
subjects [146]. However, the recent proposed criteria [147] suggest that the coexistence of 
multifocal lesions in the periventricular white matter on T2-weighted Magnetic Resonance 
Imaging (MRI) scans with or without Gadolinium (Gd) enhancement on T1-weighted MRI 
scans are needed for the diagnosis of MS. Different epidemiological studies affirm that 
exposure to an environmental factor, e.g., an infectious agent, in genetically predisposed 
individuals could be crucial for MS pathogenesis [148] above all for the effect of the traffic 
into the CNS of activated auto-reactive CD4
+
 T helper1 (Th1) [135, 149, 150]. In fact, 
infiltrating CD4
+
 T cells support the initiation of brain inflammation through the activation of 
microglia leading to the generation of Th1-mediated immuneresponses (IL-12/IFN-g and IL-
23/IL-17). On the contrary, the resolution of neuroinflammation is triggered by astrocytes, 
which promote anti-inflammatory Th2-polarized responses (IL-10 and TGF-b) and the 
elimination of infiltrating immune cells through Fas/FasL-dependent apoptosis [144, 149] 
(Figure4). 
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Figure 4. Intrathecal immune milieu in MS 
 
The presence in CSF of detectable sHLA-G levels in relapsing-remitting MS (RRMS) patients 
and, occasionally, in other inflammatory neurological disorders and non-inflammatory 
neurological disorders was reported for the first time by Fainardi and coauthors [151]. 
In addition, RRMS patients present higher sHLA-G levels in CSF than controls that was more 
increased, in association with IL-10 values, in RRMS patients without than in those with 
magnetic resonance imaging (MRI) evidence of disease activity [152]. The importance of 
sHLA-G level evaluation as a biomarker for MS is confirmed [153]. In fact, CSF 
concentrations of sHLA-G and IL-10 are positively correlated in patients with inactive MRI 
disease and CSF IL-10 titers are more elevated in patients with than in those without CSF 
measurable levels of sHLA-G.. HLA-G acts as anti-inflammatory molecules under the control 
of IL-10 CSF levels which, together with the influence of HLA-G polymorphysms, may 
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enhance sHLA-G production [154 paper attached]. In particular, we analysed the association 
of HLA-G 14bp DEL/INS and +3142 C>G polymorphisms with CSF and serum levels of 
sHLA-G molecules in a group of relapsing-remitting (RR)-MS patients, categorized 
according to MRI disease activity [154 paper attached]. The aim of our study was to better 
understand the actual role of these genetic polymorphisms in sHLA-G production occurring in 
MS, and, furthermore, to clarify whether serum and CSF sHLA-G concentrations measured in 
MS depend only on local inflammatory microenvironment, or are also influenced by the 
individual genetic background.  We found that serum and CSF sHLA-G levels were more 
elevated in high than in low DEL/INS 14bp and +3142C>G sHLA-G producers and were 
different among the various combined HLA-G genotypes in both MRI inactive and active 
diseases. The highest and the lowest sHLA-G values were identified in MS patients with 
C/C,DEL/DEL and G/G,INS/INS genotypes, respectively. Our findings suggest that serum 
and CSF sHLA-G levels in MS could be influenced by HLA-G polymorphisms irrespective of 
the inflammatory microenvironment. 
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The existence of high CSF concentrations of sHLA-G in MS patients and their association 
with clinical and MRI stable disease have been repeatedly confirmed in subsequent 
investigations [152-156]. 
Our group also focused on the identification of the presence of HLA-G dimers in CSF of MS 
patients in comparison with inflammatory and non inflammatory controls [157 paper 
attached]. We found a higher frequency of HLA-G dimers in RRMS patients that suggests 
their implication in reducing the inflammatory status in MS.  
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Interestingly, HLA-G and its inhibitory receptors (ILT-2 and ILT-4) are found strongly up-
regulated within and around MS lesions where microglia, macrophages and endothelial cells 
are recognized as the cellular sources [158]. This data agrees with our finding about HLA-G 
dimers in CFS since it is known that dimers can bind with major strength ILT-2 receptor [74]. 
Furthermore, cultured human MS microglial cells activated with Th1 proinflammatory 
cytokines have a higher HLA-G expression and a novel subpopulation of naturally occurring 
CD4
+
 and CD8
+
 Treg cells expressing HLA-G (HLA-G
+ 
Treg) [159] induced by IL-10 [160, 
161] has been recently described in peripheral blood of MS patients with relapse. Taken 
together, these observations strenghten the evidence that HLA-G antigens are likely to be 
involved in the resolution of MS autoimmunity acting as anti-inflammatory molecules and 
suggest that HLA-G
+
 Treg could play a key role in the development of a CNS 
immunosuppressive microenvironment at the sites of inflammation in MS. 
 
1.2.3 HLA-G in other inflammatory and autoimmune diseases 
HLA-G proves also to be an important biological marker in other pathologies, for example, 
gastrointestinal, allergic, and cutaneous diseases. 
Ulcerativecolitis (UC) and Crohn’s disease are characterized by a different sHLA-G 
expression pattern [162-165] by peripheral blood mononuclear cells. In particular, non-
activated peripheral blood mononuclear cells from Crohn’s disease patients produce 
spontaneously sHLA-G while those from UC patients and healthy donors do not. 
Furthermore, after stimulation with LPS, both cells from Crohn’s disease  and healthy 
subjects show sHLA-G production, while this does not happen in UC patients. The different 
HLA-G expression profiles observed in UC and Crohn’s disease patients sustain the different 
aethiopathogenesis at the origin of these two diseases. In particular, the responses to therapies 
in UC and Crohn’s disease correspond to different sHLA-G secretion levels [166]. When 
immunosuppressant therapy is administered, a normalization in the production of HLA-G 
molecules in Crohn’s disease is obsverved, while it starts the release of HLA-G in UC 
patients. These data confirm the diversity in the behavior of these two pathologies and 
propose the analysis of sHLA-G levels with the final goal of distinguishing between UC and 
Crohn’s disease patients and to monitor therapy. In particular, I investigated the association 
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between the HLA-G 14-bp deletion/insertion (DEL/INS) polymorphism and soluble (s)HLA-
G production in Tunisian patients affected by Crohn’s disease (CD). Furthermore, the 
presence of HLA-G dimer was analyzed by western Blot [167 paper attached]. We found a 
significant association concerning the genotype Ins/Ins for young-onset CD patients, but not 
with adult-onset CD patients. We observed also a significant increase in sHLA-G dosed by 
ELISA in CD patients compared to controls. Among sHLA-G positive patients, HLA-G 
dimers were found in the 43% of subjects present with a correlation to the advanced stages of 
the disease. These findings indicate that the 14-bp Del/Ins polymorphism of HLA-G gene and 
the presence of dimers are associated with the risk of CD and suggest a role for sHLA-G as 
prognostic marker for progressive disease. 
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The skin is characterized by a “skinimmunesystem (SIS),” where immune cells and humoral 
components support cutaneous inflammation. The deregulation of this skin defense 
mechanisms is evident in different inflammatory disorders of the skin, such as psoriasis, 
atopic dermatitis, pemfigo, vitiligo, and systemic sclerosis [168]. HLA-G protein normally is 
not expressed in the skin from healthy controls [169, 170], while ectopic HLA-G expression 
has been described in skin pathologies [–171-174].  
Psoriasis is a chronic inflammatory skin disease characterized by an autoimmune component. 
Both membrane-bound and soluble HLA-G proteins have been detected in psoriatic skin 
lesions with the main compound characterized by macrophage lining at the dermoepidermal 
junctions [170]. It could be speculated that the up-regulation of HLA-G molecules by 
macrophages could represent an attempt to control auto-reactive T cells, induced by activated 
keratinocytes-derived cytokines/chemokines.  
In fact, in this condition, HLA-G may modulate the activity of cytotoxic lymphocytes and 
promoting the development of Treg cells in order to prevent keratinocyte destruction [175]. 
Interestingly, psoriatic patients present lower plasma sHLA-G levels compared with controls 
[176], suggesting a difference in systemic HLA-G expression that could be associated with 
the IL-10 deficiency typical of psoriasis.  
It is possible to identify three main therapies for Psoriasis: topical drugs, light therapy,and 
systemic medications. Evaluation of therapeutic effects on sHLA-G expression has shown an 
increase in plasmatic levels of systemic treated patients (efalizumab, cyclosporinA and 
acitretin) [176] and a significant association between HLA-G14bpDEL allele and 
14bpDEL/DEL genotype with acitretin clinical out come [177 paper attached]. Thus, we can 
suppose a possible direct effect of HLA-G in antagonizing systemic Thelper1 activation that 
gives to HLA-G  a potential role as a marker of response to acitretinin psoriatic patients. 
  
 193 
 
 
 
 
Reference 177 
 194 
 
 
 
 195 
 
 
 
 
 
 196 
 
 
 
 197 
 
 
 
 
 198 
 
 
 199 
 
Conclusions and perspectives 
1. The key role of HLA-G in pathologies and infections and expected impact in 
treatment and prognosis 
The data herein summarized suggest that HLA-G may play a key role in the onset of  
infectious and autoimmune  diseases. In fact, the impication of HLA-G proteins in creating an 
impaired immune system response during autoimmunity and in the immune-escape 
mechanisms during viral infections has been here confirmed. Basing on that, it appears even 
more evident that understanding the functions of HLA-G in these disorders could help in the 
identification of new approaches to control HLA-G production [178]. HLA-G is characterized 
by a “double-faced” behaviour that explains how down/over-expression of HLA-G may not 
only act as an immunosuppressive and beneficial condition but may also sustain an 
unbalanced immune stimulation and autoimmunity. For example, during inflammatory 
cutaneous diseases there is a disproportional expression of HLA-G molecules that could lead 
to autoimmunity [176, 177]. Furthermore, several studies reported that intratecal sHLA-G 
could act as tolerogenic molecules in MS as confirmed by the disease remission associated to 
the presence of the molecule [150-158] and also a strong associatiation with RA severity and 
therapy response [45, 142] The comprehension of the specific mechanisms of action of HLA-
G in the development and progression of inflammatory and autoimmune disorders could 
justify the use of HLA-G molecules as a marker of inflammation and drug treatment, 
providing new therapeutic perspectives.  
Concerning viral and bacterial infections, the improvement in the comprehension of the role 
of HLA-G in immune-escape could help the development of new anti-viral treatments aimed  
to target HLA-G. This could represent an important advantage in therapy but also in 
prevention, above all when the infection could induce a neoplastic transformation [93] or, as 
in the case of CF patients infected by P. aeruginosa, where the possibility to modulate HLA-G 
may drastically influence the disease outcome and therapy response [123, 131]. In fact, HLA-
G alteration is observed during both viral and bacterial infections and participates in the 
manteinance of the infective status. 
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In fact, as reported in this thesis, the literature and also the studies followed during my PhD, 
suggest that HLA-G could be implicated in both risk and disease exacerbation and 
chronicization since during these pathologic contiditions this antigen is characterized  by an 
abberant expression connected to the different disease environment. In particular, HLA-G 
proteins could directly interact with immune cells or control the balance between Th1 and 
Th2 cytokines creating in this way a disequilibrium that would maintain inflammatory and 
immune-deregulated conditions and infections.  
Diagnosis and prevention of diseases is mainly based on the identification of specific 
biological markers and drug targets. In view of this, the possibility of an easy and fast 
identification of molecules, for example in biological fluids, seems to be even more 
necessary. In recent years, different studies have demonstrated that HLA-G could fulfil this 
necessity [79-83]. In fact, HLA-G expression and levels in biological fluids, cells and tissues 
in different pathological conditions have been shown. Several authors reported that the level 
of soluble HLA-G and gene polymorphisms correlate with disease outcome and the 
therapeutic success of treatment [142, 143, 179, 180].  
So in conclusion, HLA-G evaluation could represent a concrete help in outcome prediction 
and  in supporting treatment decisions. 
 
 
 
 Other works 
During my PhD course, I also worked on other topics connected to immune dysregulation in 
different pathological situations. 
I investigated the role of KIR (Killer Immunoglobulin-like receptor) receptors in HPV 
infection and the association with cervical lesions (Paper 1, paper attached) and in herpesvirus 
infection in MS patients (Paper 2, paper attached).  
I also evaluated the role of HLA-G molecules during CLL immune-escape (Paper 3, paper 
attached) and in the tolerogenic behaviour of multipotent stromal cells (Paper 4, paper 
attached). I also optimazed a Real Time PCR assay to analyse the +3142 C>G HLA-G 
polymorphism (Paper 5, paper attached). 
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